前往化源商城

80-50-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: adst_MBL_Abs_LOPAC_o1
Protocol: PROTOCOL TABLE (as described by Inglese et al., 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., enzyme, Incubation, Reagent, etc.); VALUE; DESCRIPTION
1; NDM-1; 4 uL of 3 nM enzyme in 50 mM HEPES (pH 7.0), 1 uM Zn2SO4, 0.01% Tween20; Use BioRaptr to dispense into Aurora black, clear bottom low base 1536-well plates
2; Compounds; 23 nL; Use Pin Tool (Wako) to transfer DMSO control and library compounds in DMSO
3; Incubate; >30 min
4; Reagent; 2 uL of 50 uM nitrocefin
5; Incubate; 15 min
6; Detector; Absorbance at 485 nm (bandwidth = 5 nm, 25 flashes/well) on Tecan Infinity

NOTES (numbers refer to sequence above)
1; Column 1 of each plate received assay buffer without enzyme and columns 2-48 received enzyme for a final assay concentration of 2 nM.
2; Control plate contained DMSO in columns 1, 2, 3, and 4.
3; Compound interaction with enzyme.
4; Nitrocefin substrate was prepared in the same assay buffer as step 1 for a final assay concentration of 16.7 uM and added to all wells across the assay plates.
5; Substrate interaction with enzyme, plateau phase of kinetics.
6; Default reader settings were applied for absorbance read at 485 nm, bandwidth = 5 nm, 25 flashes/well.

References:
Inglese J, Shamu CE, Guy RK. 2007. Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol. doi:10.1038/nchembio0807-438

Yasgar A, Shinn P, Jadhav A, Auld D, Michael S, Zheng W, Austin CP, Inglese J, Simeonov A. 2008. Compound Management for Quantitative High-Throughput Screening. J Lab Autom 13:79 - 89. doi:10.1016/j.jala.2007.12.004
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00619 uMActivity at 0.027 uMActivity at 0.114 uMActivity at 0.487 uMActivity at 2.090 uMActivity at 8.950 uMActivity at 38.40 uMCompound QC
Inhibitor3.981182.713284Complete curve; high efficacy-5.41.75290.998-85.2132-2.5-1.10 0 0 0 0 0 0-83.06770.331-4.4394-3.8635-4.1445-22.4953-70.2611-83.0677QC'd by SIGMA
Inhibitor3.981186.840984Complete curve; high efficacy-5.41.75290.9984-88.3409-1.5-1.10 0 0 0 0 0 0-87.1212-3.16930.9309-2.5069-4.9423-21.371-71.2523-87.1212QC'd by SigmaAldrich
Inhibitor0.63180.24967Complete curve; partial efficacy-6.21.62660.9473-77.2493-1.20 0 0 0 0 0 0-85.83221.0696-6.18312.6192-35.0701-61.102-70.3685-85.8322QC'd by SigmaAldrich
Inhibitor12.589388.882742Partial curve; partial efficacy-4.91.28760.9991-89.8827-1-2.20 0 0 0 0 0 0-72.92280.2292-0.1802-2.3293-3.1649-8.7192-35.8094-72.9228QC'd by SigmaAldrich
Inhibitor149.590924Complete curve; partial efficacy-60.70.9802-54.7627-5.1718-1.20 0 0 0 0 0 0-50.6356-4.7265-12.4822-10.3565-25.9426-34.6202-47.4071-50.6356QC'd by SigmaAldrich
Inhibitor1.412548.524523Partial curve; partial efficacy-5.851.010.9742-48.02450.5-2.20 0 0 0 0 0 1-5.3866-1.20153.7165-6.9837-9.5457-28.5518-42.1268-5.3866QC'd by SigmaAldrich
Inhibitor1.412547.865123Partial curve; partial efficacy-5.851.13410.9771-41.36516.5-2.20 0 0 0 0 0 1-9.77613.527310.31380.975-3.7801-22.4186-36.4181-9.7761QC'd by SigmaAldrich
Inhibitor1.584936.212523Complete curve; partial efficacy-5.810.9923-40.9076-4.6951-1.20 0 0 0 0 0 0-40.1923-4.7459-6.9255-4.9627-14.2109-25.8479-34.5299-40.1923QC'd by SigmaAldrich
Inhibitor2.818439.145322Complete curve; partial efficacy-5.553.51170.9704-37.64531.5-1.20 0 0 0 0 0 0-33.23162.72473.99422.4805-1.9632-8.8932-41.8091-33.2316QC'd by SigmaAldrich
Inhibitor2.818445.876422Complete curve; partial efficacy-5.553.990.9653-42.37643.5-1.20 0 0 0 0 0 0-39.79747.2065-4.30686.55423.175-6.2515-44.7929-39.7974QC'd by SigmaAldrich
Inhibitor3.981133.122222Complete curve; partial efficacy-5.44.95490.9463-34.1222-1-1.20 0 0 0 0 0 0-32.7905-0.1342.19192.9262-8.5243-1.6343-35.2983-32.7905QC'd by SigmaAldrich
Inhibitor6.309655.122122Complete curve; partial efficacy-5.24.0950.936-51.62213.5-1.20 0 0 0 0 0 0-51.37890.5554-5.641315.5056.32571.1919-41.3451-51.3789QC'd by SigmaAldrich
Inhibitor11.220239.186521Partial curve; partial efficacy-4.954.0950.9644-38.18651-2.20 0 0 0 0 0 0-37.67263.1453.48662.08582.7632-4.7161-10.9003-37.6726QC'd by SIGMA
Inhibitor12.589345.266821Partial curve; partial efficacy-4.91.53860.9942-45.7668-0.5-2.20 0 0 0 0 0 0-38.97230.58140.0974-2.57190.1212-3.5588-16.4873-38.9723QC'd by SIGMA
Inhibitor7.943344.626321Partial curve; partial efficacy-5.11.88510.9397-47.1263-2.5-2.20 0 0 0 0 0 0-43.2775-5.18330.5249-9.91921.4034-2.4109-28.628-43.2775QC'd by SigmaAldrich
Inhibitor7.943348.629421Partial curve; partial efficacy-5.11.96730.9929-48.12940.5-2.20 0 0 0 0 0 0-46.1345-2.21980.63082.7203-0.6777-1.7104-26.4066-46.1345QC'd by SigmaAldrich
Inhibitor12.589357.340421Partial curve; partial efficacy-4.91.1110.9981-61.2084-3.868-2.20 0 0 0 0 0 0-48.5781-2.8067-4.3234-4.2172-4.6882-11.4388-26.203-48.5781QC'd by SigmaAldrich
Inhibitor14.125442.469721Partial curve; partial efficacy-4.851.37230.9681-44.4697-2-2.20 0 0 0 0 0 0-36.0871.1661-0.154-5.6091-4.8499-4.5006-16.2964-36.087QC'd by SigmaAldrich
Inhibitor15.848947.714721Partial curve; partial efficacy-4.80.90.9119-53.648-5.9333-2.20 0 0 0 0 0 0-40.6424-9.3389-1.6111-11.1336-11.9209-12.5232-20.6469-40.6424QC'd by SigmaAldrich
Inhibitor5.011924.352121Complete curve; partial efficacy-5.31.62590.9356-31.4557-7.1036-1.20 0 0 0 0 0 0-30.7964-4.521-7.6934-11.6677-4.253-12.6621-24.1646-30.7964QC'd by SigmaAldrich
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1315
Protocol: Cybrid cells were washed with PBS, trypsinized, spun down at 300g for 5 minutes, and resuspended in 10 mLs of PBS. Cells were counted, and the appropriate amount of cells were added to a vial containing DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose, DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 0.3% DMSO, DMEM No Glucose + 2% FBS + 1% P/S + 10mM Galactose + 1uM I-BET GSK 525762A, or DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 1.25mM Glucose. Cells were then seeded in a Corning 3570 384-well plate (40 ul/well,1500 cells/well). Two replicates were prepared as described at the same time per library plate.

100 nl of compound was added to each well via pin transfer immediately after seeding. After the addition of compound, cells were incubated for 72 hours at 37 degrees C with 5% CO2.

Following the 72 hour incubation period, the 384 well plates were centrifuged for 1 minute at 1000 rpm. The media was aspirated using an aspiration wand and fresh media DMEM only, was added to the cells (40uL/ well) using a well-mate. Fifteen-microliters of Cell Titer Glow substrate was then added to each well using the well-mate. The plates were gently vortexed for 10 seconds and then centrifuged for 1 minute at 1000 rpm. The plates were then immediately read on the Envision instrument and the luminescence was detected for each individual well.

Positive control (strong): Cells seeded in DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 1.25mM Glucose
Positive control (weak): Cells seeded in DMEM No Glucose + 2% FBS + 1% P/S + 10mM Galactose + 1uM I-BET GSK 525762A
Negative control: Cells seeded in DMEM (No Glucose) + 2%FBS + 1% P/S + 10mM Galactose + 0.3% DMSO
Comment: Data analysis method and criteria for scoring active compounds:

Z-scores were calculated for both replicates separately using the plate average and standard deviation of experimental well luminescence (Z = (x - mu)/sigma). Compounds were considered active if both replicate Z-scores >= 1.8. Activity scores were determined by scaling replicate average Z-scores from 0 (activity score = 0) to 4 (activity score = 100), with activity score > 45 being considered active. Z-scores < 0 were set to activity score = 0; Z-scores > 4 were set to activity score = 100 (100% activity).
Luminescence_ALuminescence_BZ-score Rep AZ-score Rep B
15087591941614-0.29-0.43
17411761927012-0.01-0.44
197614624877510.290.11
347045740451192.151.64
244929828664190.880.48
15633732388055-0.230.01
182721124299270.10.05
235000430356-1.88-1.91
15443152345114-0.25-0.03
182392827546700.10.37
10776522101177-0.83-0.27
190465327072880.20.33
327799138504031.911.45
16951292723755-0.060.34
401368547421142.822.33
245078133481490.880.96
253134330714220.980.69
229493728987220.680.52
16507292422255-0.120.05
12125591703208-0.66-0.66
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1149-MLP
Protocol: A 558 bp region upstream of hspX was PCR amplified and cloned upstream of the GFP-mut2 (Cormack et al., 1996). This construct was cloned into a modified version of the replicating plasmid pSE100 and transformed into CDC1551 to generate CDC1551(hspX'::GFP).

The M. tuberculosis CDC 1551 (hspX'::GFP) fluorescent biosensor was grown in pH 7.0 Middlebrook 7H9 medium to mid- to late-log phase. Black-walled, clear-bottom, tissue-culture treated 384-well microtiter plates (Corning #3712) were filled with 25 uL of buffered pH 7.0 7H9 medium using a Matrix Combi. 100 nL of compound was then transferred to each well via stainless steel pin array. Plates were manually sealed with DMSO-resistant aluminum seals and frozen at -80C until they were ready to be screened. The cultures were re-suspended in pH 7.0 7H9 and 25 uL was dispensed into each well of the 384-well assay plates already containing the perturbator utilizing a Cy-Bio Selma liquid handler robot to an OD595 of 0.05. The plates were then placed in a Ziploc bag with a moistened paper towel (to limit evaporation) and incubated for 6 days at 37C. Fluorescence and optical density (OD) readings were made on an EnSpire plate reader (Perkin Elmer, Inc.) at excitation and emission wavelengths of 488 and 509 nm as a top read, with the OD being taken at 595 nm as a bottom read.

The ~328,633 compound library was arrayed into black-walled, clear-bottom tissue-culture treated 384-well microtiter plates (Corning #3712) by pin transfer (100 nL), containing 25 uL of buffered pH 7.0 7H9 medium. In a previous screen utilizing the same compound library and screening method, four random compound plates were screened in duplicate to observe variation in hit robustness across plates and method. The result was that the duplicate plates did not vary in a statistically significant manner and due to the high volume of compounds to be screened (~328,633), replicates were not utilized.

Negative control: DMSO, 0.1% final concentration in buffered pH 7.0 7H9 in column 2 or column 23 of each plate

Positive control: 0.3 uM Rifampicin final concentration in buffered pH 7.0 7H9 in column 1 or column 24 of each plate
Comment: Analysis methods:
To calculate normalized fluorescence percent inhibition, plate average negative control fluorescence intensity (based on all plates within a screening run) was subtracted from well fluorescence intensity, divided by the difference between plate negative and positive control average fluorescence intensity (based on all plates within a screening run), and multiplied by 100. To calculate normalized growth inhibition, plate average negative control absorbance (based on all plates within a screening run) was subtracted from well absorbance, divided by the difference between plate negative and positive control average absorbance (based on all plates within a screening run), and multiplied by 100. Normalized fluorescence percent inhibition was divided by normalized growth inhibition to calculate a ratio. Wells were considered active if growth was not greatly decreased and showed either a 3-fold selectivity fluorescence to growth inhibition ratio (with 35-45% fluorescence inhibition) or a 1.5-fold selectivity fluorescence to growth inhibition ratio (with > 45% fluorescence inhibition). These compounds may be directly or indirectly inhibiting DosRS signaling. Wells were considered general inhibitors of M. tuberculosis growth if both fluorescence and growth inhibition > 50%. Activity scores were scaled from 100 to 0 and derived from normalized fluorescence percent inhibition, with 100 (or > 100) = 100% inhibition and 0 (or < 0) = no inhibition.
FluorescenceAbsorbanceRatioNormalized Fluorescence InhibitionNormalized Growth InhibitionNormalized FI:GI RatioGeneral Inhibition
361550.2851268608.990745.250731.71228
367210.2811306807.519896.929291.08523
388660.291340211.945723.152540.617191
373140.281332645.978877.348930.81357
359490.2791288499.526077.768571.22623
359210.2871251609.598834.411462.17589
362680.2931237828.697091.893624.59283
392470.321226470.955621-9.43663-0.101267
386200.2861350352.584994.83110.535074
373510.2841315185.882725.670371.03745
380970.2831346183.94416.090010.647635
378520.2951283124.580781.054344.34468
372680.2981250606.09841-0.204574-29.8103
396530.284139623-0.09944285.67037-0.0175373
377440.2931288194.861441.893622.56727
377300.2871314634.897824.411461.11025
391230.3011299771.27786-1.46349-0.873157
366370.2871276557.738184.411461.75411
405660.327124055-2.47204-12.37410.199775
393340.2861375310.7295364.83110.151008
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Center for Chemical Genomics, University of Michigan 靶标:N/A
External ID: TargetID_659_CEMA
Protocol: Black, standard capacity streptavidin-coated 384-well plates (Pierce 15407) were first washed with 50 L of phosphate buffer (100 mM, pH 7.0; PB7) three times using a Biotek 405 ELX plate washer. Subsequently, 5 L of biotinylated pre-miRNA substrate (500 nM final) was dispensed into the plate using a Multidrop Combi Reagent Dispenser (Thermo Scientific). Plates were then centrifuged for 1 min at 1,000 RPM (223 g), sealed with plate tape, and incubated overnight at 4 C. The following morning, plates were washed three times with 50 L of PB7, followed by the addition of 5 L of Dicer digest buffer (20 mM Tris, 12 mM NaCl, 2.5 mM MgCl2, 1 mM fresh DTT, and 4.5% DMSO) and centrifugation. Compounds (50 nL of 5 mM DMSO stock, 25 M final) were then added into the sample wells using a Sciclone (Caliper) liquid handler with V&P pintool; the same volume of DMSO was added to the control wells. The plates were incubated at 25 C for 15 min before addition of 5 L of digest buffer containing 217 g/nL Dicer (108 g/mL Dicer, 5% glycerol and 0.01% Triton X-100 final, excess with respect to pre-miRNA). For the positive control wells, digest buffer without Dicer was added. The plates were centrifuged again and resealed before being placed in a 37 C incubator for 5 h. After Dicer cleavage, plates were washed three times with 50 L of PB7. mTet-HRP in PB7 (10 L, 750 nM final) was then dispensed into each well. The plates were subsequently centrifuged, sealed, and incubated at 25 C for 2 h. Plates were then washed three times with 50 L of wash buffer (2 mM imidazole, 260 mM NaCl, 0.5 mM EDTA, 0.1% Tween-20, pH 7.0), followed by washing three additional times with 50 L of PB7. Finally, SuperSignal West Pico (25 L; Pierce) was added, the plates were incubated at 25 C for 5 min, and chemiluminescence signal was detected using a PHERAstar plate reader using LUM plus module (BMG Labtech).
Comment: The activity outcome is based on a Z-score (number of standard deviations from the negative control mean) of 3 or higher on at least 50% times that the sample was screened.

For instance, if the sample was screened in n=4 runs, it would be considered active only if it had a Z-score of 3 or above in at least 2 runs.
Z_SCORE
2.91
-0.56
0.61
2.15
0.54
-0.32
1.12
-0.07
0.61
1.55
-0.77
-0.76
-2.08
0.67
-0.35
0.17
-1.42
-0.64
-5.35
1.42
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:
External ID: HMS1303
Protocol: Prior to screening, lyophilized FITC-GIV peptide (a.a. 1671-1701) is dissolved in 100% DMSO to a concentration of 0.5 mM, then further diluted with water to a final concentration of 50 microM. One stock was prepared in batch for the entire screen and aliquoted. All protein stocks were stored at -80C. Thawing of aliquots on the day of the assay was performed rapidly at room temperature.

Prior to transfer of screening compounds, experimental wells of 384-well assay plates were pre-filled with 37.8 nM of FITC-GIV peptide (for 25 nM final concentration) in a 10 microL volume of assay buffer (50 mM Tris [pH 7.4], 100 mM NaCl, 10 mM MgCl2, 5 mM EDTA, 0.4% NP-40, 30 microM GDP, 1 mM DTT). Control wells were pre-filled with 37.8 nM of FITC-GIV peptide in 10 microL of assay buffer containing either 1% DMSO (vehicle negative control) or 45.3 microM AlCl3+15.1 mM NaF (AlF4- positive control). Each plate contained 16 negative control and 16 positive control wells. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface. Following, 100 nL of experimental compound was pin-transferred into individual wells for each of two replicate assay plates (A&B). After pin-transfer, 5 microL of 3 microM His-tagged rat Galphai3 purified from E. coli (for 1 microM final concentration) was added to each well, and assay plates were shaken at low speed for 5 seconds. Final assay volume was 15 microL. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface and shaken for 10 seconds prior to an incubation of 90 minutes at room temperature. Plates were protected from prolonged light exposure. All manipulations were performed at room temperature.

Assay plates were read with a PerkinElmer Wallac EnVision Multilabel 2103 plate reader using the fluorescent polarization measurement technology with a D505fp/D535 dual mirror and a 480 nm excitation filter. 535 nm emission filters were used for P and S channel reads at 11 mm measurement height with 30 flashes and detector gains of 319 and 563. G-factor 0.96.

Negative control: DMSO
Positive control: Aluminum tetrafluoride (AlF4-, composite of NaF and AlCl3)
Comment: Calculated result values and scoring of active compounds:

Z-score: Indicates the number of standard deviations an experimental condition is from the mean. It is calculated based on plate average (u) and standard deviation (s) of experimental well fluorescence polarization (FP) measurements for each replicate. Z-score (z) is defined as the quotient of the mean of the experimental well population subtracted from an individual well's FP (x), divided by the standard deviation within the experimental wells; z = (x-u)/s.

Normalized percent control: calculated by subtracting plate average positive control FP from experimental well FP, dividing by the difference between plate average negative and positive control FP, and multiplying by 100.

STD: the number of standard deviations from the plate average negative control FP for each replicate experimental well

Compound wells with FP values exceeding +5 standard deviations from the negative control sample average were flagged as potential aggregators or fluorescence quenchers due to their high polarization signal (HighPol) and were excluded from further consideration. Activity scores were calculated by averaging the replicate normalized percent of control values and subtracting from 100 (score based on single replicate if data for other replicate was excluded for any reason). Result values < 0 were set to 0 (no activity) and > 100 were set to 100 (100% activity). Compounds with activity score >= 15 were considered active.
mP_AFluorTotal_APchan_ASchan_AmP_BFluorTotal_BPchan_BSchan_BZ-score_AZ-score_BPercent Ctrl_APercent Ctrl_BSTD_ASTD_BNote: Polarization Artifact
122.41957988860658427448204128.11963767260572207523232-1.18225-0.63523293.2647101.541-1.80030.362745
124.61958252660565717469384129.81962517560450197535137-0.634716-0.19961197.3807104.669-0.7001171.09906
124.21966389660838267496244126.21969903460848867529262-0.734268-1.122196.632498.0451-0.90015-0.460198
1231973179861103407511118126.71971411360873537539407-1.03292-0.99397994.387398.965-1.50025-0.243634
128.11989636061370667622228130.519724618607261775793840.236366-0.0202377103.929105.9571.050181.40225
125.61986771661402087587300131.31967349360531227567249-0.3858350.1847699.2516107.429-0.2000331.74875
127.72002396861782517667466128.819866494612424676180020.136814-0.455859103.181102.8290.8501420.665934
129.21961772360456307526463132.719789155608172076257150.5101340.543507105.987110.0051.600272.35513
130.91974707560775087592059133.819696771604822176003290.9332310.82538109.167112.0292.450412.83157
127.41995714661589967639154131.119907155612592276553110.06214940.133511102.619107.0610.7001171.66213
128.61970436060754757553410127.919896451613799676204590.360806-0.686482104.864101.1731.300220.276119
126.51975466161009937552675131.21981143860959967619446-0.1618430.159136100.935107.2450.2500421.70544
125.21989803761513307595377128.51982052261116137597296-0.485388-0.53273398.5033102.277-0.4000670.535996
125.21974444761039237536601130.11961319460400397533116-0.485388-0.12273798.5033105.221-0.4000671.229
127.41996280061609707640860131.319894559612117976522010.06214940.18476102.619107.4290.7001171.74875
128.82002040261715807677242132.519888130611339976613320.4105820.492258105.239109.6371.400232.26851
128.31997122561589057653415131.820071564617330377249580.2861420.312884104.303108.3491.150191.96532
128.7197498216088940757194112919670633606278775450590.385694-0.404609105.051103.1971.350230.752559
125.719727542609617775351881291962415560487067526743-0.360947-0.40460999.4387103.197-0.1500250.752559
127.82004995261859487678056130.820021937616251676969050.1617020.0566366103.368106.5090.900151.53219
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: GPx1-biochemical-p4-p7
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent 1; 3 uL; GPx1 enzyme or no enzyme control in 1536-well, black, solid Greiner assay plate.
2; Compound; 25 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head.
3; Incubation; 30 min; room temperature.
4; Reagent 2; 1 uL; 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA substrate
5; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.
6; Incubation; 15 min; room temperature.
7; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.

NOTES (numbers refer to Sequence numbers above)
1. 3 uL of 16.66 nM GPX1 and 0.016% BSA in assay buffer (50 mM Tris-HCl, 2 mM EDTA (pH 7.5), 150 mM NaCl) was added to columns 3-48 of 1536-well assay plates using a BioRAPTR Flying Reagent Dispenser (Let's Go Robotics (LGR), Carlsbad, CA). A no-enzyme control (0.01% BSA in TES assay buffer) was added to columns 1-2.
2. 25 nL of test compounds and DMSO controls were added to each well with a pin tool (Kalypsys).
3. The assay plates were incubated for 30 minutes at room temperature.
4. 1 uL of master mix (500 nM glutathione reductase (GR), 5 mM reduced glutathione (GSH), 2.5 mM NADPH in assay buffer) was added. 1 uL of cumene hydroperoxide (CHP) ([2.5 mM] in 50% EtOH) was then added within 5 minutes to initiate the reaction. Final concentrations were: 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA.
5. Initial fluorescence readout (t=0) at 340/450 nm was measured using a ViewLux multimodal detector (PerkinElmer, Waltham, MA).
7. Endpoint fluorescence readout (t=15) at 340/450 nm was measured 15 min after room temperature incubation.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000080000 uMActivity at 0.0000294000 uMActivity at 0.0000322389 uMActivity at 0.0000640000 uMActivity at 0.0001602685 uMActivity at 0.0003305803 uMActivity at 0.0007029698 uMActivity at 0.00145 uMActivity at 0.00305 uMActivity at 0.00484 uMActivity at 0.00883 uMActivity at 0.016 uMActivity at 0.036 uMActivity at 0.076 uMActivity at 0.127 uMActivity at 0.227 uMActivity at 0.400 uMActivity at 1.089 uMActivity at 1.958 uMActivity at 4.491 uMActivity at 9.517 uMActivity at 15.29 uMActivity at 27.66 uMActivity at 48.83 uMActivity at 98.28 uMActivity at 150.0 uMCompound QC
Inhibitor1.153584.01186Complete curve; high efficacy-5.9382.95230.9935-85.511-1.5-1.10 0 0 0 0 0 1000.55170-10.1942-66.3862-86.37470QC'd by MedChem Express
Inhibitor4.0381107.130985Complete curve; high efficacy-5.39381.10.9833-107.6309-0.5-1.10 0 0 0 0 0 0-99.10763.0643-3.35612.7295-17.6643-28.702-81.8703-99.1076QC'd by Prestwick
Inhibitor4.5309100.661985Complete curve; high efficacy-5.34381.46410.9928-111.2365-10.5746-1.10 0 0 0 0 0 0-102.4277-6.7289-14.1368-11.7774-11.5064-34.358-88.9997-102.4277QC'd by Glixx
Inhibitor3.207694.995685Complete curve; high efficacy-5.49381.69240.997-110.0264-15.0308-1.10 0 0 0 0 0 0-108.5073-10.859-15.7072-17.8113-19.7979-44.1871-99.3353-108.5073QC'd by MedChem Express
Inhibitor3.207694.333585Complete curve; high efficacy-5.49381.55790.9917-98.6297-4.2962-1.10 0 0 0 0 0 0-97.268-10.9671-0.2469-8.8219-8.6028-35.074-85.0291-97.268QC'd by Vitas
Inhibitor4.0381101.224485Complete curve; high efficacy-5.39382.24810.9999-101.22440-1.10 0 0 0 0 0 0-101.0224000.6663-1.57-17.0563-89.6716-101.0224QC'd by DC Chemicals
Inhibitor4.5309102.529384Complete curve; high efficacy-5.34381.88510.9958-104.0293-1.5-1.10 0 0 0 0 0 0-100.803500-6.96670.0183-19.6985-87.3271-100.8035QC'd by MedChem Express
Inhibitor5.152590.153784Complete curve; high efficacy-5.2881.96730.9895-98.5024-8.3487-1.10 0 0 0 0 0 0-96.571-12.4368-8.9031-14.8602-3.6239-19.2852-77.5914-96.571QC'd by EMD Chemicals
Inhibitor6.496.476183Complete curve; high efficacy-5.19383.92950.9988-94.97611.5-1.10 0 0 0 0 0 0-95.357503.3535002.0026-79.8012-95.3575QC'd by Microsource
Inhibitor6.489.09983Complete curve; high efficacy-5.19384.44950.9997-88.5990.5-1.10 0 0 0 0 0 0-88.422200.5042.224300-77.8921-88.4222QC'd by SigmaAldrich
Inhibitor4.0928572.588765Partial curve; high efficacy-5.3882.90231-572.58870-2.10 0 0 0 0 0 100000-52.3008-521.48330QC'd by Microsource
Inhibitor2.547977.642365Complete curve; partial efficacy-5.59384.50450.9919-92.3162-14.6738-1.20 0 0 0 0 0 0-90.5524-12.7147-12.5699-11.8115-21.2763-34.6101-93.8172-90.5524QC'd by SIGMA
Inhibitor2.023979.203365Complete curve; partial efficacy-5.69381.1110.9975-92.0986-12.8952-1.20 0 0 0 0 0 0-89.2428-13.3008-14.4831-11.996-25.7417-51.5286-82.1843-89.2428QC'd by SIGMA
Inhibitor2.547939.753164Complete curve; partial efficacy-5.59384.50450.9617-72.8813-33.1282-1.20 0 0 0 0 0 0-68.5285-37.2443-35.4912-31.4131-28.8568-43.7703-77.3346-68.5285QC'd by Microsource
Inhibitor5.7812259.6350Partial curve; high efficacy-5.2381.69240.9999-259.630-2.10 0 0 0 0 0 0-250.1252000-1.0316-34.0768-179.1962-250.1252QC'd by Adooq
Inhibitor4.0928222.462650Partial curve; high efficacy-5.3882.58840.9995-221.46261-2.10 0 0 0 0 0 100003.8047-24.8352-196.33210QC'd by Glixx
Inhibitor18.0377742.537649Partial curve; high efficacy-4.74382.72021-741.53761-2.10 0 0 0 0 0 0-698.2464003.833500-124.2034-698.2464QC'd by Vitas
Inhibitor16.0761622.503649Partial curve; high efficacy-4.79382.25261-622.50360-2.10 0 0 0 0 0 0-576.39220000-5.8017-157.3588-576.3922QC'd by Glixx
Inhibitor16.0761415.830746Partial curve; high efficacy-4.79382.25260.9995-418.3307-2.5-2.10 0 0 0 0 0 0-387.3433-6.004500-3.7575-3.0222-113.565-387.3433QC'd by SIGMA
Inhibitor16.2936426.190146Partial curve; high efficacy-4.7882.72020.9998-425.69010.5-2.10 0 0 0 0 0 0-400.838100003.5739-74.4409-400.8381QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: cib1-v1-fp-lopac
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 3 uL; Protein or buffer (4/3x)
2; Compound; 46 nL; Control inhibitor / compound library
3; Time; 15 min; Room temperature incubation
4; Reagent; 1 uL; Fluorescent labeled peptide (4x)
5; Time; 1000 rpm; Centrifuge
6; Time; 15 min; Room temperature incubation
7; Detection; Ex 480/ Em 540; ViewLux Fluorescence Read

NOTES (numbers refer to sequence above)
1; Protein Mixture: C1B1-GST (final concentrations of 1 uM). Buffer composition: 5 mM HEPES pH 7.4, 125 mM NaCl, 5 mM CaCl2, 0.01% Tween20.
2; Control Inhibitor: unlabeled peptide (final concentration range 17.4 nM to 572 uM). Compound Library final concentration range 18.3 nM to 114 uM.
3; Room temperature incubation.
4; Fluorescent Labeled Peptide: FITC-aIIb (final concentration of 100 nM). Sequence of alphaIIb peptide: Acetyl-LVLAMWKVGFFKRNRK-FITC (purity is 95.83%).
5; Centrifuge 1000 rpm (164 g) for 15 seconds.
6; Room temperature incubation.
7; ViewLux Fluorescent Polization Read: excitation = 480(20) / emission = 540(25) S and P; FITC Dichroic mirror.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.457 uMActivity at 2.290 uMActivity at 11.40 uMActivity at 57.10 uMActivity at 114.0 uMCompound QC
Inactive00047.97775.218613.21832.88075.14317.9777QC'd by SIGMA
Inactive0-5.254.95490.78024.510.540 0 0 0 04.81458.380612.50713.21345.47894.8145QC'd by SIGMA
Inactive0-6.254.95490.6118-2.10793.540 0 0 0 10.77892.0284-4.2566-1.0182-0.59080.7789QC'd by SIGMA
Inactive00043.57742.38233.86868.2512.01483.5774QC'd by SIGMA
Inactive000410.38079.895.918111.4919.356810.3807QC'd by SIGMA
Inactive0-4.34.95490.6272-4.04822.540 0 0 0 12.42543.92840.19853.7517-1.70682.4254QC'd by SIGMA
Inactive0-6.253.92950.7726-0.60696.540 0 0 0 0-2.58914.3389-1.0785-0.00880.7325-2.5891QC'd by SIGMA
Inactive0-4.110.6094151.257540 0 0 0 011.0674.8012-0.61874.74545.008111.067QC'd by SIGMA
Inactive0-5.80.50.99370.51040 0 0 0 01.4316.82144.5993.16091.62171.431QC'd by SIGMA
Inactive0-5.753.51170.334511.5840 0 0 0 011.16748.067810.485814.2068.429611.1674QC'd by SIGMA
Activator44.668417.50Partial curve; partial efficacy; poor fit-4.350.30.5917213.52.40 0 0 0 015.9596.6539.006811.64018.938815.959QC'd by SIGMA
Inactive00045.8632.93888.37043.67094.32195.863QC'd by SIGMA
Inactive0-44.0950.4043-2.8717240 0 0 0 0-1.14311.3342-0.17344.61831.5532-1.1431QC'd by SIGMA
Inactive0-6.254.95490.516310.5540 0 0 0 09.78116.559812.035911.67457.82369.7811QC'd by SIGMA
Inactive000411.14538.912711.250616.76477.346711.1453QC'd by SIGMA
Inactive0-5.354.95490.621211440 0 0 0 09.27045.61082.505315.32668.369.2704QC'd by SIGMA
Inactive0-44.95490.5331-4.83282.540 0 0 0 0-2.36060.78591.09176.05482.0406-2.3606QC'd by SIGMA
Inactive0-5.354.95490.96150.5095.540 0 0 0 00.67935.52425.628-0.40921.0110.6793QC'd by SIGMA
Inactive0-6.254.95490.86260.449940 0 0 0 01.79316.6174-0.87580.7592-0.83651.7931QC'd by SIGMA
Inactive0-4.33.92950.7001-3.73360.540 0 0 0 0-3.5281.1629-1.35772.2632-2.0565-3.528QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR513
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-8.61372.09370.7210-9.347240 0 0 0 0 0 0 0-1.1981-7.7893-1.3061-0.91362.7218-2.44492.34910.5984-1.1981QC'd by EnamineInactive0004-2.1799-5.7621-6.6695
Inactive0-5.76374.95490.7632-7.8669040 0 0 0 0 0 0 0-9.70720.11940.8287-2.1801-1.25493.4297-9.8891-4.5089-9.7072QC'd by EnamineInactive0-4.21373.24750.7579-22.3272-240 0 0 0 0 0 0 0-18.1894-7.6164-4.6343
Cytotoxic48.557732.580620Single point of activity-4.31373.29750.9389-34.0806-1.5-30 0 0 0 0 0 0 0-30.48392.00771.2353-4.12-5.6743-2.5921-0.0827-2.7826-30.4839QC'd by EnamineInactive0-4.46372.90230.9774-26.7175-0.540 0 0 0 0 0 0 0-25.1812-1.37171.1119
Inactive0004-4.0244-1.58150.55321.86960.2877-1.0948-0.97181.3168-4.0244QC'd by EnamineInactive00042.6212-1.36331.1082
Inactive0-4.313710.6075-12.9835-1.540 0 0 0 0 0 0 0-9.1529-6.26020.8875-0.2672-1.0757-1.1078-3.3998-4.2513-9.1529QC'd by SIGMAInactive0-4.16374.44950.8449-13.8135-140 0 0 0 0 0 0 0-11.0946-2.2814-1.8218
Inactive0004-2.2635-3.2218-1.5002-3.2094-6.5467-6.9838-9.2586-2.3579-2.2635QC'd by SIGMAInactive0004-2.1934-6.1949-2.9926
Inactive0004-3.6053-10.98-3.1918-5.1884-6.2628-0.9809-3.7687-3.2149-3.6053QC'd by SIGMAInactive0004-2.2311-5.3121.6461
Cytotoxic48.557749.883420Single point of activity-4.31373.29750.9731-52.7952-2.9118-30 0 0 0 0 0 0 0-47.5721-5.7276-1.70880.07121.5459-4.3172-5.7565-4.7314-47.5721QC'd by SIGMACytotoxic68.589655.54720Single point of activity-4.16373.990.9932-57.6622-2.1152-30 0 0 0 0 0 0 0-44.4411-3.0449-2.577
Inactive0-6.36370.20.60998-9.656340 0 0 0 0 0 0 05.2888-8.0469-2.15330.5824-6.7160.56390.89561.59855.2888QC'd by SIGMAInactive0-5.26371.22210.9111-12.426240 0 0 0 0 0 0 15.0335-0.8992.8828
Inactive0-4.16374.44950.8402-12.6467040 0 0 0 0 0 0 0-10.1223-1.34671.9663-1.54012.2503-0.6504-1.39571.3844-10.1223QC'd by SIGMAInactive0004-5.9601-4.8718-1.2894
Inactive0-7.06374.95490.7513-8.96612.540 0 0 0 0 0 0 0-15.38840.7062.90453.3353-8.2144-8.9894-9.0163-3.1514-15.3884QC'd by SIGMAInactive0-4.36373.62720.923-19.77080.540 0 0 0 0 0 0 0-18.5592.3106-3.7006
Cytotoxic43.277175.632420Single point of activity-4.36373.29750.9904-76.4078-0.7754-30 0 0 0 0 0 0 0-70.38471.99022.3693-0.9536-1.7116-0.7698-5.276-6.3803-70.3847QC'd by SIGMACytotoxic48.557782.719420Single point of activity-4.31373.29750.9843-85.6388-2.9194-30 0 0 0 0 0 0 0-76.6203-7.7845-4.8132
Inactive0-4.41370.70.7291-12.603140 0 0 0 0 0 0 0-8.83580.5447-0.27422.49020.87441.9273-4.8205-1.4703-8.8358QC'd by SIGMAInactive0004-3.8112-0.6122-0.8775
Inactive0004-4.7292-2.4847-4.1876-6.48671.0395-0.71620.0299-0.793-4.7292QC'd by SIGMAInactive00042.63140.3943-1.3136
Inactive0-5.81371.64360.80470.5-6.497440 0 0 0 0 0 0 0-0.4266-9.1645-5.8022-3.6937-7.1147-4.6312-0.94771.1703-0.4266QC'd by SIGMAInactive0-4.31374.50450.829513.5-1.965340 0 0 0 0 0 0 012.7252-3.68221.1451
Cytotoxic24.336549.095240Partial curve; partial efficacy-4.61374.50450.9503-50.0798-0.9846-2.20 0 0 0 0 0 0 0-50.0782-0.0272.3579-4.7322-0.13674.7681-8.001-12.0828-50.0782QC'd by SIGMACytotoxic34.376251.39520Partial curve; partial efficacy-4.46371.66040.9408-52.4652-1.0701-2.20 0 0 0 0 0 0 0-46.02210.25280.4999
Inactive0-5.86374.95490.5635-7.1429-140 0 0 0 0 0 0 11.7155-3.0936-3.86271.08310.1892-0.7274-10.5357-4.05151.7155QC'd by LightBiologicalsInactive00041.3344-8.4864-3.5514
Inactive0-8.01374.95490.8219-1.5-15.383740 0 0 0 0 0 0 0-0.1642-15.3198-14.49810.2013-6.9242.4229-4.18230-0.1642QC'd by SIGMAInactive0-5.01374.95490.41315-2.544240 0 0 0 0 0 0 03.88070.31652.8847
Inactive0-7.96374.95490.6746-2.3322740 0 0 0 0 0 0 17.57815.96367.5271-8.1935-0.710.9919-1.6782-0.86047.5781QC'd by SIGMAInactive0-6.11372.72020.84876-3.067540 0 0 0 0 0 0 06.1795-3.1652-6.3062
Cytotoxic43.277130.71920Partial curve; partial efficacy; poor fit-4.36371.46410.9032-33.219-2.5-2.40 0 0 0 0 0 0 0-27.6825-1.9081-4.6287-2.873-0.37610.9727-8.0988-6.6948-27.6825QC'd by SIGMAInactive0-4.76371.88510.9867-25.4518-0.540 0 0 0 0 0 0 0-24.5432-1.7780.5931
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR845
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-6.71373.990.74483.5-3.097940 0 0 0 0 0 0 1-4.53010.5359-3.9754-6.3316-1.5343.70283.02253.9166-4.5301QC'd by EnamineInactive0-4.36374.50450.860920.5-2.001440 0 0 0 0 0 0 019.79981.4656-7.5012
Inhibitor38.570835.180610Partial curve; partial efficacy; poor fit-4.41370.30.5495-40.7918-5.6112-2.40 0 0 0 0 0 0 0-30.6598-14.2189-5.7598-1.3427-19.1905-11.1974-18.7235-15.3163-30.6598QC'd by EnamineInactive0-8.76374.95490.5011-5.7381240 0 0 0 0 0 0 0-4.77690.9052-7.1733
Inhibitor43.277177.03210Single point of activity-4.36373.29750.9971-78.3429-1.3109-30 0 0 0 0 0 0 0-72.2295-0.848-0.118-4.2082-0.6518-1.8942-0.08-5.3518-72.2295QC'd by EnamineInhibitor43.277163.648410Single point of activity-4.36372.95230.9946-65.7144-2.0659-30 0 0 0 0 0 0 0-59.6321-2.31811.0274
Inactive0-4.61374.0950.7785-11.2649040 0 0 0 0 0 0 0-11.05412.37760.40940.2158-4.58290.01091.9949-2.9254-11.0541QC'd by EnamineInactive0-4.41373.92950.7033-11.88-140 0 0 0 0 0 0 0-11.56670.6312.2683
Inhibitor13.685430.707521Partial curve; partial efficacy-4.86371.3310.9362-34.9705-4.2631-2.20 0 0 0 0 0 0 0-32.0588-3.9769-3.3008-9.2624-0.6359-6.9717-5.8106-24.2995-32.0588QC'd by SIGMAInhibitor19.331244.710720Partial curve; partial efficacy-4.71374.95490.9424-44.06730.6434-2.20 0 0 0 0 0 0 0-43.91873.3929-7.8909
Inactive0-4.61370.50.86281.139-21.207340 0 0 0 0 0 0 0-4.0509-23.9228-19.6932-21.9663-17.0189-16.3805-16.3485-13.4943-4.0509QC'd by SIGMAInactive0-4.56370.60.86232.9723-21.743540 0 0 0 0 0 0 0-2.5231-21.0888-19.8358
Inactive0-4.66374.0950.7922-16.0186740 0 0 0 0 0 0 0-15.43222.495111.00468.413812.5339-0.02468.6463-1.6168-15.4322QC'd by SIGMAInactive0-4.16374.95490.6395-12.122540 0 0 0 0 0 0 0-8.851710.91192.0118
Inhibitor43.277176.013310Single point of activity-4.36373.29750.9556-72.62463.3888-30 0 0 0 0 0 0 0-67.00170.43212.27294.102815.2231-2.70330.1771-0.4468-67.0017QC'd by SIGMAInhibitor68.589678.061510Single point of activity-4.16374.95490.8832-73.18654.8751-30 0 0 0 0 0 0 0-58.3846-2.614-4.3734
Activator1.219732.68440Complete curve; partial efficacy; poor fit-5.91370.80.948130.5-2.18441.40 0 0 0 0 0 0 029.0103-1.64831.5958-4.32031.836314.835216.647829.69429.0103QC'd by SIGMAActivator48.557744.5940Single point of activity-4.313710.538947.78773.193730 0 0 0 0 0 0 038.027214.7051.0969
Inactive0-4.61374.0950.9713-21.2654-1.540 0 0 0 0 0 0 0-21.0545-2.7301-0.41341.0029-2.2409-1.0812-2.1276-6.3156-21.0545QC'd by SIGMAInactive0-4.41373.990.8429-24.48221.540 0 0 0 0 0 0 0-23.7352-0.6662-2.5056
Activator17.2289133.59920Partial curve; high efficacy-4.76371.55790.9975127.2961-6.30312.10 0 0 0 0 0 0 0117.8667-8.9515-6.7202-3.1268-8.6465-1.68023.809264.311117.8667QC'd by SIGMAActivator21.6899164.62480Partial curve; high efficacy-4.66371.24750.9927156.6074-8.01742.10 0 0 0 0 0 0 0133.1695-7.9286-14.0417
Inhibitor68.589698.74510Single point of activity-4.16374.95490.931-122.9328-24.1879-30 0 0 0 0 0 0 0-104.5347-33.7189-31.4897-29.5277-32.0771-19.6494-24.4139-12.4858-104.5347QC'd by SIGMAInhibitor68.589665.97810Single point of activity-4.16374.44950.9656-93.0438-27.0659-30 0 0 0 0 0 0 0-79.0031-29.1044-30.014
Inactive0-4.11374.95490.6653-23.47291.540 0 0 0 0 0 0 0-16.22742.7934.6828-5.1704-5.88253.40514.4085.1222-16.2274QC'd by SIGMAInactive0004-8.3878-2.7507-9.7834
Inactive0-6.96374.50450.52725-3.781740 0 0 0 0 0 0 012.2006-2.9898-3.919-4.81813.02829.0156-2.12881.783312.2006QC'd by SIGMAInactive0-4.61374.95490.8110.5-1.339640 0 0 0 0 0 0 010.67871.3266-2.2209
Inactive0-4.81370.50.790222-1.879740 0 0 0 0 0 0 016.0881-1.9337-0.9491-0.2665-4.06648.70261.96710.79316.0881QC'd by SIGMAInactive0-4.81371.78850.535915.5-0.482940 0 0 0 0 0 0 014.811-5.402411.5478
Activator5.448365.90960Complete curve; high efficacy-5.26373.51170.992865.1288-0.78081.10 0 0 0 0 0 0 064.12783.4298-0.9076-4.3967-2.59521.436710.934765.698664.1278QC'd by SIGMAActivator8.6349121.11690Partial curve; high efficacy-5.06371.17050.9968115.9495-5.16742.10 0 0 0 0 0 0 0108.5669-5.4351-5.5745
Inactive0-5.71374.95490.595-8.7497040 0 0 0 0 0 0 15.4059-2.6152-3.8122-2.09634.4994.406-9.7914-7.14735.4059QC'd by LightBiologicalsInactive0-4.11374.95490.3408-10.3215040 0 0 0 0 0 0 0-7.3513-4.35072.8856
Inactive0-7.31371.22210.9525-1.4634-23.351240 0 0 0 0 0 0 1-12.6292-20.3271-25.7094-13.6954-6.9291-1.6842-1.5865-0.8028-12.6292QC'd by SIGMAInactive0-6.96372.40640.4996-15.2703040 0 0 0 0 0 0 0-27.72521.4691-2.4748
Activator5.448383.66690Complete curve; high efficacy; poor fit-5.263710.969688.03014.36321.31 0 0 0 0 0 0 082.872636.415612.07881.2155-2.961220.571436.413270.139882.8726QC'd by SIGMAActivator5.4483159.39970Partial curve; high efficacy-5.26370.50.9946149.0275-10.37222.10 0 0 0 0 0 0 0117.16-5.2091-4.8857
Inhibitor68.589652.742510Single point of activity-4.16374.95490.7907-52.540.2025-30 0 0 0 0 0 0 0-42.826-0.156510.14883.0709-2.1032-5.5467-13.87819.2268-42.826QC'd by SIGMAInhibitor68.589648.042810Single point of activity-4.16374.95490.7805-49.2366-1.1938-30 0 0 0 0 0 0 0-40.11641.4546-2.3883
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC981
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.86371.47810.785.5-8.060740 0 0 0 0 0 0 04.915-11.7172-10.2261-5.6747-3.2162-8.4895-6.42940.12124.915QC'd by EnamineInactive0-4.71374.95490.71496.5-4.107540 0 0 0 0 0 0 06.3707-4.6171-5.2048
Inactive0-6.66374.95490.6015-3.7977240 0 0 0 0 0 0 0-5.28490.7910.92684.1721.3686-5.48181.3153-6.0814-5.2849QC'd by EnamineInactive0-5.81374.95490.3563-3.9449240 0 0 0 0 0 0 0-7.65024.16730.1723
Cytotoxic0.769679.126986Complete curve; high efficacy-6.11372.40640.989-80.2129-1.086-1.10 0 0 0 0 0 0 0-74.1102-5.396-2.9033-0.44662.7921-36.8956-82.6325-83.0675-74.1102QC'd by EnamineCytotoxic0.685977.815120Complete curve; high efficacy; poor fit-6.16372.40640.9961-79.552-1.7369-1.31 0 0 0 0 0 0 0-75.8034-72.1781-1.7358
Inactive0004-3.6673-6.0811-7.2954-2.9298-5.4835-6.4501-0.8482-0.7681-3.6673QC'd by EnamineInactive00041.9261-2.3973-1.7209
Inactive00043.10533.4072-1.20312.5309-0.51780.13742.52470.33163.1053QC'd by SIGMAInactive00040.58950.0467-1.1307
Inactive0-8.81374.95490.3082-4.4311740 0 0 0 0 0 0 0-0.12874.6299-9.52591.88571.5028-8.8402-7.8944-7.173-0.1287QC'd by SIGMAInactive0-7.21374.95490.6151-5.42113.540 0 0 0 0 0 0 13.27414.48891.0958
Inactive0-4.11374.95490.5878-11.9248-140 0 0 0 0 0 0 0-8.6874-2.6017-2.1396-4.8238-0.7809-0.22621.32562.5681-8.6874QC'd by SIGMAInactive0004-3.0350.9522-1.0902
Cytotoxic24.336546.215220Partial curve; partial efficacy-4.61374.0950.8819-45.84720.3681-2.20 0 0 0 0 0 0 0-45.43845.881-8.1203-9.15891.98714.56915.5262-10.7271-45.4384QC'd by SIGMACytotoxic34.376235.963320Partial curve; partial efficacy; poor fit-4.46371.10.6483-38.4633-2.5-2.40 0 0 0 0 0 0 0-30.38613.9144-10.9322
Inactive0-6.71373.990.8426-7.88744.540 0 0 0 0 0 0 0-2.89953.23475.85414.84131.1609-11.9895-9.9614-6.4748-2.8995QC'd by SIGMAInactive0-6.21374.95490.3993-9.8085-140 0 0 0 0 0 0 1-4.23611.05812.2314
Inactive0004-8.8762-5.923-4.3846-2.7844-3.0174-1.57820.44671.6153-8.8762QC'd by SIGMAInactive0004-2.6033-0.7522-0.3781
Cytotoxic13.685431.192220Partial curve; partial efficacy; poor fit-4.86374.0950.987-28.69222.5-2.40 0 0 0 0 0 0 0-29.32691.0510.82913.02485.19882.44540.8952-21.0544-29.3269QC'd by SIGMACytotoxic30.637939.175420Single point of activity-4.51372.63840.9942-36.67542.5-30 0 0 0 0 0 0 0-33.8452.13522.347
Cytotoxic38.570879.766740Partial curve; high efficacy-4.41372.63840.9853-84.0115-4.2449-2.10 0 0 0 0 0 0 0-76.5239-2.4554-4.41340.9249-10.1622-3.8808-5.616-14.7247-76.5239QC'd by SIGMACytotoxic54.482785.061720Single point of activity-4.26373.24750.9911-91.6046-6.5429-30 0 0 0 0 0 0 0-78.4884-7.7514-8.9605
Cytotoxic19.331237.87620Partial curve; partial efficacy-4.71371.62590.9556-35.95541.9206-2.20 0 0 0 0 0 0 0-33.29621.1258-0.21948.2922-0.93250.73450.067-16.4636-33.2962QC'd by SIGMACytotoxic24.336537.729420Single point of activity-4.61374.95490.9857-38.7294-1-30 0 0 0 0 0 0 0-38.4602-3.9414-2.1898
Inactive0004-2.46990.42311.17392.4494-2.3903-5.8621-2.75422.1121-2.4699QC'd by SIGMAInactive0004-2.214-1.4625-2.7485
Inactive0-4.66374.0950.741112.5-2.679940 0 0 0 0 0 0 012.3306-2.456-4.37830.7114-1.00270.4255-9.31662.996712.3306QC'd by SIGMAInactive0-4.16374.95490.944819.50.267340 0 0 0 0 0 0 015.7501-0.36041.1005
Cytotoxic24.336530.069120Single point of activity-4.61374.0950.9268-30.5691-0.5-30 0 0 0 0 0 0 0-30.4742-6.1565-0.15064.9067-0.89490.097-0.2413-8.1828-30.4742QC'd by SIGMACytotoxic30.637941.734320Single point of activity-4.51373.29750.9593-36.23435.5-30 0 0 0 0 0 0 0-33.40166.88037.6192
Inactive0-5.86370.40.90196.5-8.152440 0 0 0 0 0 0 04.1776-6.9275-6.6426-8.0437-2.1876-0.6978-1.40723.42914.1776QC'd by LightBiologicalsInactive00046.6773-1.88140.4883
Inactive0-4.61374.50450.9231100.077740 0 0 0 0 0 0 010.0385-0.48612.253-0.50310.15970.9668-0.76862.389210.0385QC'd by SIGMAInactive00047.4959-0.5175-0.4627
Inconclusive0.153632.691210Partial curve; partial efficacy; poor fit-6.81370.20.930116-16.69122.40 0 0 0 0 0 0 011.0017-10.576-3.6335-2.6864-0.78383.31442.74056.346611.0017QC'd by SIGMAInactive0-5.01371.75290.63996.5-1.856440 0 0 0 0 0 0 06.2964-1.41730.4366
Cytotoxic48.557732.238220Partial curve; partial efficacy; poor fit-4.31371.10.9013-36.0152-3.7769-2.40 0 0 0 0 0 0 0-26.6793-0.5468-5.0549-6.9535-0.2308-5.7352-8.0532-10.5038-26.6793QC'd by SIGMAInactive0-4.61371.46410.9003-22.7063-2.914740 0 0 0 0 0 0 0-20.1719-4.0675-2.6739
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:HCMV UL50
External ID: HMS1262
Protocol: NEC is stored at -80 degrees at a concentration of 15mg/ml in single use aliquots.

On the day of the screen, 20ul of purified NEC is aliquoted using a Multidrop Combi reagent dispenser into 384 well plates (Corning 3824). 100nl of compound dissolved in DMSO was transferred to each well of the assay plated via pin transfer. The plates (NEC + compound) are incubated at room temperature for 3 hours. Acceptor and donor reagents (CisBio 620/665 pair) are combined then added to each well at 5 microL volumes at a concentration of 8 nM and 80nM respectively. The plates are spun at 1k rpm for 1 min and incubated overnight at 4 degrees, then for one hour the subsequent day at room temperature.

Flourescent measurements are read on the Envision 1 plate reader at ICCB-L. The raw data consists of two fluorescence readings - at 665 nm and 620 nm for the acceptor and donor respectively.
Comment: Data analysis:
The raw data consists of two fluorescence readings - at 665 and 620 nm for the acceptor and donor respectively. The data is processed as a ratio of the emission from the acceptor over the donor (homogeneous time resolved fluorescence ratio). Normalized percent inhibition (NPI) for all experimental wells is calculated based on plate averages for negative and positive control HTRF ratio. Positives are scored as any ratio with a 50% or greater inhibition as compared with the positive control (i.e. NEC + Untagged UL50). To be considered a hit, both replicates need to score as positive. Activity scores are derived from NPI, with 100 = 100% inhibition (> 100% set to 100) and 0 = no inhibition (< 0% set to 0). Note that some compounds with NPI <50% (activity scores < 50) are classified as potential hits based on additional criteria (typically by selecting wells with low ratios compared to other experimental wells on the plate).
HTRF-Ratio_Avg.NPIHTRF-Ch1_AHTRF-Ch2_AHTRF-Ratio_AHTRF-Ch1_BHTRF-Ch2_BHTRF-Ratio_BHTRF-Ratio_Avg
2.3176387444236941789570632533624515
4.8173477312237241725770712440524064.5
4.2178687517237701815873952455424162
17.3118447012168911320463922065718774
6.6122586577186381432165022202620332
18.1115616789170291351266662027018649.5
-3.9111135694195171195949422419921858
10.3122156757180781398865062150019789
-20.7104254592227031187645852590224302.5
14.4123566766182621385868882011919190.5
5.8128686545196611401766002123820449.5
15.8122056703182081347068181975718982.5
3.2117425785202971292760542135320825
10.3122416415190821349065872048019781
-2.3109485353204521253054992278621619
9.1126446696188831392066202102719955
8.7134437082189821445368632105920020.5
-27100444376229521140941492749825225
10115506340182181327961962143219825
3.7107655590192581246756062223920748.5
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC428
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive00042.40140.97590.30781.8904-1.32141.1138-1.6886-2.57882.4014QC'd by EnamineInactive00042.2787-0.9694-3.8908
Inactive0004-2.9424-0.1831-2.1441-0.81230.7356-2.795-3.3133-0.3073-2.9424QC'd by EnamineInactive00041.5663-0.9898-2.1656
Inhibitor1.933130.25050Complete curve; partial efficacy-5.71374.95490.9884-32.7505-2.5-1.20 0 0 0 0 0 0 0-32.7088-2.9131-4.6477-3.9229-1.60220.1764-32.5182-31.28-32.7088QC'd by EnamineInhibitor2.16935.34080Complete curve; partial efficacy; poor fit-5.66374.95490.9534-35.28250.0583-1.41 0 0 0 0 0 0 0-36.4368-31.3574-4.1999
Inactive00044.2421-5.00691.1218-0.01471.4143-0.7153-1.8654-1.08794.2421QC'd by EnamineInactive0004-2.4793-2.9079-3.184
Inactive0-4.21373.990.5455-9.5512040 0 0 0 0 0 0 0-7.9593-4.54884.51660.2512-0.7312-1.48191.47-0.0426-7.9593QC'd by SIGMAInactive0004-11.2315-5.6697-2.8914
Inactive0004-4.1758-2.8245-1.44510.5422-0.3307-1.02441.9480.1256-4.1758QC'd by SIGMAInactive00041.6001-3.85641.804
Inactive00044.3768-4.084-2.0739-1.1987-0.2477-0.4857-0.73983.08794.3768QC'd by SIGMAInactive00043.4197-0.1470.119
Inactive0-4.41374.0450.787-9.44140 0 0 0 0 0 0 0-9.1167-0.88074.7479-0.5740.36761.5356-0.56610.5529-9.1167QC'd by SIGMAInactive0-4.16374.95490.9155-18.8168-0.540 0 0 0 0 0 0 0-15.264-3.64431.0791
Inactive00044.56840.73691.2152-0.4642-5.3740.7893-5.2966-0.6674.5684QC'd by SIGMAInactive00043.07711.5072-1.0121
Inactive00045.87980.9788-0.8043-0.16830.5835-0.00870.8357-0.43085.8798QC'd by SIGMAInactive00043.0034.6097-0.2019
Inactive0-4.71370.9310.966716-12.66240 0 0 0 0 0 0 011.1718-11.0163-13.0889-15.135-12.7909-8.7096-8.71320.854911.1718QC'd by SIGMAInactive0-4.66374.0950.96819-8.276140 0 0 0 0 0 0 018.8245-9.1995-8.5885
Inactive0-4.16374.95490.9451-31.7539-2.540 0 0 0 0 0 0 0-26.4616-3.7295-5.2291-3.0969-2.288-3.5247-2.32081.7484-26.4616QC'd by SIGMAInactive0-4.16374.95490.9334-30.6082-2.540 0 0 0 0 0 0 0-25.5069-2.7103-5.3426
Inactive0-4.71374.95490.9407-8.8985040 0 0 0 0 0 0 0-9.08210.3128-1.43780.2924-0.419201.586-4.053-9.0821QC'd by SIGMAInactive0-4.51370.80.6738-13.3555140 0 0 0 0 0 0 0-9.46290.6379-2.0412
Inactive0-8.41370.70.5837-1.07391040 0 0 0 0 0 0 00.29827.47482.23922.15450.68180.246-6.31161.35580.2982QC'd by SIGMAInactive0-6.91374.95490.486-0.784640 0 0 0 0 0 0 00.21723.73181.5014
Inactive0004-2.40140.9093-2.3514-1.26-1.532-1.0946-1.4276-1.3037-2.4014QC'd by SIGMAInactive0004-0.9775-6.6823-0.2967
Activator12.197242.828241Complete curve; partial efficacy-4.91372.95230.987642.7435-0.08481.20 0 0 0 0 0 0 042.6198-2.2542-2.3630.4008-0.30113.44693.268732.944442.6198QC'd by SIGMAActivator15.355343.419221Partial curve; partial efficacy-4.81371.46410.904646.68233.26312.20 0 0 0 0 0 0 043.806214.88091.3724
Inactive00041.3627-0.0701-2.08231.36830.09830.2791.0733-2.83051.3627QC'd by LightBiologicalsInactive0004-0.91481.1123-2.0113
Inactive0-4.61374.0950.936610-2.575240 0 0 0 0 0 0 09.8552-1.1769-2.1967-4.1352-1.5482-4.2293-3.65290.53249.8552QC'd by SIGMAInactive0-4.16374.95490.901717.5-2.621540 0 0 0 0 0 0 013.8866-3.2503-5.5179
Activator7.695944.941241Complete curve; partial efficacy-5.11371.75290.977743.3726-1.56861.20 0 0 0 0 0 0 042.7055-6.7239-3.17491.0732-2.18933.30557.112735.965142.7055QC'd by SIGMAActivator30.637938.378610Partial curve; partial efficacy; poor fit-4.51370.90.890248.3786102.41 1 1 0 0 0 0 038.606523.46220.9144
Inactive0-5.81371.55790.9841-8.5398140 0 0 0 0 0 0 11.1671.751.36320.05350.9714-1.3806-6.7289-8.36651.167QC'd by SIGMAInactive0-5.51372.72020.8571-9.4462040 0 0 0 0 0 0 12.69632.31221.1111
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:SIRPalphatyrosine-protein phosphatase non-receptor type substrate 1 isoform 1 precursor [Homo sapiens]
External ID: adst-pstx-s1-lance-lopac-o1
Protocol: PROTOCOL TABLE (as described by Miller, T. et al. 2019)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1a. Reagent. 3 uL CD47-His (12.5 nM) and Anti-His Eu Donor reagent (3 nM) added to respective wells in Assay buffer; white/solid bottom high base, med bind 1536-well plates (Greiner 789075)
1b. Reagent. 2 uL Assay buffer negative control for background fluorescence
2. Reagent. 23 nL library compounds (7-pt, 1:4 intraplate titration series) or DMSO control transferred by Pin Tool
3. Centrifuge. Centrifuge plate for 30 s at 1000 RPM
4. Incubation.#Incubate reagents at room temperature for 30 min, protected from light
5. Reagent. 2 uL SIRPalpha-biotin (100 nM) in Assay buffer
6. Incubation.#Incubate reagents at room temperature for 30 min, protected from light
7. Reagent. 1 uL SAV-APC (26 nM) acceptor reagent added to respective wells
8. Centrifuge. Centrifuge plate for 30 s at 1000 RPM
9. Incubation. Incubate reagents at room temperature for 30 min, protected from light
10. Detector. Measure Top TR-FRET on EnVision (Eu/APC filter set); calculate ratio Ch1/Ch2

Notes
1. Assay buffer composition.#Phosphate buffered saline (PBS; 10 mM Phosphate, 137 mM NaCl, and 2.7 mM KCl; pH 7.4), 0.05% IGEPAL CA-630

2. 23nL of LOPAC128 library compounds (7 plates) or DMSO vehicle control transferred to 9 Greiner white/solid bottom high base, TC plates in 7 interplate 1:5 titrations (see Yasgar, A. et al. 2008) with Pintool. Two of the 9 plates are DMSO-only in compound field at beginning and end of compound library-treated plates.

10. Detector settings#Mirror = LANCE/DELFIA Dual Enh; Ex. Filter = UV2[TRF] 320; Em. Filter = APC 665; 2nd Em. Filter = Europium 615; Measurement h = 6.5; Ex. light (%) = 100; Delay = 60 us; Window t = 100 us; No. Seq. windows = 1; Time between flashes = 2000us; No. of flashes = 100; No. of flashes for 2nd detector = 100; Calculation: "Ratio Ch1/Ch2"
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10.
PhenotypePotencyEfficacyAnalysis Commentdonor-Activity_Scoredonor-Curve_Descriptiondonor-Fit_LogAC50donor-Fit_HillSlopedonor-Fit_R2donor-Fit_InfiniteActivitydonor-Fit_ZeroActivitydonor-Fit_CurveClassdonor-Excluded_Pointsdonor-Max_Responsedonor-Activity at 0.00245 uMdonor-Activity at 0.012 uMdonor-Activity at 0.061 uMdonor-Activity at 0.307 uMdonor-Activity at 1.530 uMdonor-Activity at 7.660 uMdonor-Activity at 38.30 uMacceptor-Activity_Scoreacceptor-Curve_Descriptionacceptor-Fit_LogAC50acceptor-Fit_HillSlopeacceptor-Fit_R2acceptor-Fit_InfiniteActivityacceptor-Fit_ZeroActivityacceptor-Fit_CurveClassacceptor-Excluded_Pointsacceptor-Max_Responseacceptor-Activity at 0.00245 uMacceptor-Activity at 0.012 uMacceptor-Activity at 0.061 uMacceptor-Activity at 0.307 uMacceptor-Activity at 1.530 uMacceptor-Activity at 7.660 uMacceptor-Activity at 38.30 uMratio-Activity_Scoreratio-Curve_Descriptionratio-Fit_LogAC50ratio-Fit_HillSloperatio-Fit_R2ratio-Fit_InfiniteActivityratio-Fit_ZeroActivityratio-Fit_CurveClassratio-Excluded_Pointsratio-Max_Responseratio-Activity at 0.00245 uMratio-Activity at 0.012 uM
Inactive0-4.8334.0450.923-6.1187040 0 0 0 0 0 0-5.93220.61590.2410.0935-1.4249-0.0068-0.3772-5.93220004-5.5063-0.1723-0.57510.7557-3.0631-1.10360.8654-5.50630-6.4833.51170.4394-0.3798140 0 0 0 0 0 0-0.06691.1251-0.5578
Inactive00042.06183.53481.88793.12611.83650.58121.74092.061800044.68094.2126-0.13166.33133.97260.76944.35524.680900040.71680.8162-3.1078
Inactive00040.04260.36370.2379-0.0267-0.66740.43760.77650.04260004-0.0729-2.30580.5005-0.2315-1.1401-0.88410.2182-0.07290004-0.7474-0.9557-0.7724
Inactive0004-0.5785-0.52642.4189-1.3085-3.3725-0.4224-0.181-0.578500040.84320.92351.1709-1.3207-1.1371.60492.15110.84320-5.4830.9310.58763-0.220440 0 0 0 0 0 1-0.02810.7911-1.8504
Inactive0-4.5834.95490.9821-10.0717-0.804340 0 0 0 0 0 0-8.8097-1.0552-0.4388-0.2536-1.1953-1.2849-0.4494-8.80970-4.7331.85790.9557-12.4436140 0 0 0 0 0 0-9.53641.16241.94190.08381.3127-0.6334-1.054-9.536400041.2310.3450.6304
Inactive00046.78184.34033.42836.63334.4285.53527.26126.78180-6.5330.30.922411-2.523240 0 0 0 0 0 08.602-0.4360.64444.41834.21234.72417.80978.6020-6.9830.20.91744.5-5.872140 0 0 0 0 0 02.5711-3.2268-1.1037
Inactive00042.38461.4603-0.72962.91574.4021.472.05492.38460-7.3334.44950.67175.50.540 0 0 0 0 0 06.79761.21190.02084.47957.78772.6914.72966.79760-5.3330.40.97033.5-0.622140 0 0 0 0 0 02.2338-0.1103-0.5185
Inactive0-4.5834.95490.7258-4.30711.540 0 0 0 0 0 0-3.58921.732-0.49633.07112.63860.52551.9777-3.58920-4.7332.35310.6387-3.5105340 0 0 0 0 0 0-2.50882.07710.83145.73223.60962.08532.2571-2.508800040.52760.5074-0.4889
Inactive0-4.8830.80.789-6.00223.540 0 0 0 0 0 0-3.33522.28693.41994.50834.7576-0.05070.5826-3.33520-4.6834.0950.4289-2.1444340 0 0 0 0 0 0-1.7871.10893.84542.88656.0822-0.25412.8505-1.7870-5.2334.95490.73083.5-0.625340 0 0 0 0 0 10.8888-1.20340.6071
Inactive0004-1.19972.3747-0.30691.41541.3737-2.1914-0.6032-1.199700044.63242.92170.51962.60742.4041-0.49091.89684.63240-4.3330.70.54684.50.764940 0 0 0 0 0 02.90540.68391.1585
Inactive0004-3.57781.00310.54361.65330.1511.0493-0.0249-3.57780-4.8332.47290.6177-2.6274340 0 0 0 0 0 0-2.18952.59210.30495.39184.53423.2551.9816-2.18950-5.1834.95490.4363-1.93730.540 0 0 0 0 0 10.87931.78690.0429
Inactive00041.55212.75712.55752.54830.8590.27370.68551.552100043.90373.80064.0746.07944.02053.34552.40543.903700041.75861.21331.8451
Inactive0004-1.5996-0.406-1.8355-2.1243-0.6544-2.2117-1.5847-1.59960004-1.1277-0.2712-0.5681-1.29350.7671-1.8695-0.3285-1.12770004-0.13190.28680.8146
Inactive0-8.1330.90.8513-0.38071040 0 0 0 0 0 0-2.81737.67013.13591.14060.75540.95730.4299-2.81730-8.33310.82851.51040 0 0 0 0 0 00.09457.45683.65150.70761.45422.99961.8770.09450-5.8834.95490.95362.5-0.230340 0 0 0 0 0 02.3479-0.09440.2145
Inactive0-4.5334.95490.7336-5.7334140 0 0 0 0 0 0-4.36120.26933.37081.5837-0.65760.55591.2518-4.36120004-1.19710.51163.65142.83891.67812.94170.0459-1.19710-5.1834.95490.7788-2.22040.540 0 0 0 0 0 12.2230.375-0.033
Inactive00040.2409-2.85152.74011.3491.06360.67750.76960.240900041.19026.8633.38113.34261.34252.36382.05221.190200040.35170.5074-0.3208
Inactive00040.10.20750.08370.1157-1.68220.122.35690.100041.3498-0.04461.0531-2.06961.10960.90861.79081.349800040.6595-0.11031.2873
Inactive0004-10.7798-4.7652-0.4963-4.5841-4.8185-1.66770.0918-10.77980-4.6334.95490.9761-14.5118-0.540 0 0 0 0 0 0-13.3431-1.8437-0.0346-1.205-0.7808-0.49780.3285-13.34310004-0.35170.41910.7724
Inactive00046.49321.86214.70280.19981.22421.24142.05086.493200043.58112.09081.9577-0.04082.18492.37081.45883.58110-9.3830.40.32320.1604240 0 0 0 0 0 00.52760.3751.6735
Inactive0-8.4834.95490.89827-1.540 0 0 0 0 0 06.15740.17177.4247.09785.29997.07787.73486.15740-8.2332.90230.91257-5.071640 0 0 0 0 0 07.6443-4.22635.63296.18834.50687.18198.60097.64430-7.0330.60.84821-2.089640 0 0 0 0 0 00.8353-1.7414-1.4589
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR136
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.51374.95490.98419.5-3.038640 0 0 0 0 0 0 019.3676-2.3612-2.8082-5.4488-2.2489-2.9112-3.4175-1.559219.3676QC'd by EnamineInactive0004-5.35172.0093-6.4777
Inhibitor48.557736.21060Partial curve; partial efficacy; poor fit-4.31370.90.8071-45.4474-9.2368-2.40 0 0 0 0 0 0 0-34.4298-9.7122-4.364-11.671-16.6813-9.6787-15.4098-16.2365-34.4298QC'd by EnamineInactive0004-11.0366-0.9734-7.3298
Inhibitor43.277183.00920Single point of activity-4.36373.29750.9949-84.0538-1.0446-30 0 0 0 0 0 0 0-77.6923-3.87922.7538-2.3693-0.5727-1.6659-0.0681-5.2567-77.6923QC'd by EnamineInhibitor43.277179.45370Single point of activity-4.36372.95230.9963-81.306-1.8523-30 0 0 0 0 0 0 0-73.3378-0.46270.1851
Inactive0-4.46373.1320.7667-13.4494-140 0 0 0 0 0 0 0-12.8745-0.32052.0373-3.4545-4.74620.00971.7226-2.7713-12.8745QC'd by EnamineInactive0-4.31373.19250.8101-17.6246-240 0 0 0 0 0 0 0-15.9372-5.0774-4.5471
Inhibitor19.331245.63620Partial curve; partial efficacy-4.71374.95490.9167-45.62720.009-2.20 0 0 0 0 0 0 0-45.72563.2263-6.99944.18433.6048-8.45733.4843-19.3083-45.7256QC'd by SIGMAInhibitor21.689948.50050Partial curve; partial efficacy-4.66374.0950.955-49.3184-0.8179-2.20 0 0 0 0 0 0 0-48.9059-6.2148-3.7555
Inactive0-4.16371.1110.75881.2662-20.645940 0 0 0 0 0 0 0-7.6949-23.8716-19.2362-23.8279-16.4076-18.7298-19.3953-17.0738-7.6949QC'd by SIGMAInactive0-4.16371.53860.83570.58-19.195640 0 0 0 0 0 0 0-7.0166-20.3188-16.6054
Inactive0-4.66374.0950.806-16.89936.540 0 0 0 0 0 0 0-16.999410.73521.88666.048412.4092-0.01887.5808-1.5316-16.9994QC'd by SIGMAInactive0-4.16374.95490.883-20.90586.540 0 0 0 0 0 0 0-15.75492.18169.7822
Inhibitor43.277177.27130Single point of activity-4.36374.0950.9569-75.45791.8134-30 0 0 0 0 0 0 0-72.17882.6525-2.2372-1.501514.6872-2.40990.1529-0.4232-72.1788QC'd by SIGMAInhibitor68.589681.50290Single point of activity-4.16374.95490.9901-81.48520.0177-30 0 0 0 0 0 0 0-66.2581-2.2615-3.7766
Activator4.85583010Complete curve; partial efficacy; poor fit-5.31370.70.85413441.40 0 0 0 0 0 0 029.44141.61752.942113.13381.613413.135714.4628.542729.4414QC'd by SIGMAActivator34.376255.960710Partial curve; partial efficacy; poor fit-4.46370.60.793556.35420.39352.40 0 0 0 0 0 0 042.9205-1.42611.3781
Inhibitor68.589634.50210Partial curve; partial efficacy; poor fit-4.16374.95490.973-35.5021-1-2.40 0 0 0 0 0 0 0-29.1684-3.6431-0.38770.690.44960.0486-2.95930.4695-29.1684QC'd by SIGMAInactive0-4.61374.0950.9877-26.8039-1.540 0 0 0 0 0 0 0-26.5033-0.4236-2.0019
Activator21.6899156.736741Partial curve; high efficacy-4.66371.64360.9965152.646-4.09072.10 0 0 0 0 0 0 0139.0219-7.688-5.9205-2.6984-6.44832.92063.305165.1579139.0219QC'd by SIGMAActivator21.6899162.56741Partial curve; high efficacy-4.66371.1110.9904149.6613-12.90572.10 0 0 0 0 0 0 0123.4829-22.2955-11.9211
Inhibitor68.5896112.34550Single point of activity-4.16374.95490.9828-132.1561-19.8107-30 0 0 0 0 0 0 0-111.2426-20.1826-20.8287-18.7981-28.0886-17.1914-20.5085-12.8968-111.2426QC'd by SIGMAInhibitor68.589686.73230Single point of activity-4.16374.44950.9873-113.865-27.1328-30 0 0 0 0 0 0 0-95.3644-28.9816-26.9911
Inactive0-7.66373.92950.7686-7.2282.540 0 0 0 0 0 0 0-11.02341.09824.1458-4.8418-4.8691-9.443-3.8914-6.5282-11.0234QC'd by SIGMAInactive0-4.16374.95490.651-27.8917-340 0 0 0 0 0 0 0-23.2431-6.656-9.2309
Inactive0-4.41371.3310.898714-3.05240 0 0 0 0 0 0 011.0873-2.5867-3.2326-5.0433-4.6999-1.27990.11610.26511.0873QC'd by SIGMAInactive0-4.36374.0450.886215-0.287740 0 0 0 0 0 0 014.36781.375-2.3231
Inactive0-6.16370.20.775424-16.551840 0 0 0 0 0 0 017.516-13.7932-1.0086-0.097-3.61628.21882.019310.451717.516QC'd by SIGMAInactive0-4.76371.37230.927516.5-1.30240 0 0 0 0 0 0 014.8217-2.0042-1.1245
Activator6.85978.349582Complete curve; high efficacy-5.16372.35310.993574.2594-4.091.10 0 0 0 0 0 0 074.1184-4.5486-4.6511-8.825-2.30471.465710.463767.365974.1184QC'd by SIGMAActivator10.8707114.427843Partial curve; high efficacy-4.96371.47810.9985115.03150.60372.10 0 0 0 0 0 0 0113.44331.03430.5738
Inactive0-6.51374.95490.5499-7.6782040 0 0 0 0 0 0 1-1.3248-6.98861.92394.42461.2121-9.7318-6.8313-5.9944-1.3248QC'd by LightBiologicalsInactive0004-8.6845-1.797-2.7987
Inactive0-5.41370.80.90046-18.099440 0 0 0 0 0 0 1-21.7232-17.1597-21.7495-14.3887-17.1525-11.21-8.4462.3181-21.7232QC'd by SIGMAInactive0-5.21372.09370.8981-0.2998-16.214240 0 0 0 0 0 0 1-31.9687-17.1088-15.6886
Activator7.6959120.525544Partial curve; high efficacy-5.11370.70.9928114.4923-6.03322.10 0 0 0 0 0 0 096.374-4.3635-4.0674-6.7463-2.631320.309836.671572.031796.374QC'd by SIGMAActivator21.6899154.602341Partial curve; high efficacy-4.66370.70.9681162.64828.04592.11 0 0 0 0 0 0 0124.921836.981711.0863
Inhibitor68.589653.68390Single point of activity-4.16374.95490.8843-56.1458-2.4619-30 0 0 0 0 0 0 0-46.1475-3.3066-1.056-2.431-2.1781-4.9409-11.84398.4719-46.1475QC'd by SIGMAInhibitor68.589653.39790Single point of activity-4.16373.990.8078-57.5482-4.1503-30 0 0 0 0 0 0 0-45.11221.3906-2.0624
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:SIRPalphatyrosine-protein phosphatase non-receptor type substrate 1 isoform 1 precursor [Homo sapiens]
External ID: adst-pstx-s1-trfret-lopac-o2
Protocol: PROTOCOL TABLE (as described by Miller, T. et al. 2019)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1a. Reagent. 3 uL CD47-His (12.5 nM) and Anti-His Eu Donor reagent (0.7 nM) added to respective wells in Assay buffer; white/solid bottom high base, med bind 1536-well plates (Greiner 789075)
1b. Reagent. 2 uL Assay buffer negative control for background fluorescence
2. Reagent. 23 nL library compounds (7-pt, 1:4 intraplate titration series) or DMSO control transferred by Pin Tool
3. Centrifuge. Centrifuge plate for 30 s at 1000 RPM
4. Incubation.#Incubate reagents at room temperature for 30 min, protected from light
5. Reagent. 2 uL SIRPalpha-biotin (100 nM) in Assay buffer
6. Incubation.#Incubate reagents at room temperature for 30 min, protected from light
7. Reagent. 1 uL SAV-XL665 (85 nM) acceptor reagent added to respective wells
8. Centrifuge. Centrifuge plate for 30 s at 1000 RPM
9. Incubation. Incubate reagents at room temperature for 30 min, protected from light
10. Detector. Measure Top TR-FRET on EnVision (Eu/APC filter set); calculate ratio Ch1/Ch2

Notes
1. Assay buffer composition.#Phosphate buffered saline (PBS; 10 mM Phosphate, 137 mM NaCl, and 2.7 mM KCl; pH 7.4), 0.05% IGEPAL CA-630

2. 23nL of LOPAC128 library compounds (7 plates) or DMSO vehicle control transferred to 9 Greiner white/solid bottom high base, TC plates in 7 interplate 1:5 titrations (see Yasgar, A. et al. 2008) with Pintool. Two of the 9 plates are DMSO-only in compound field at beginning and end of compound library-treated plates.

10. Detector settings#Mirror = LANCE/DELFIA Dual Enh; Ex. Filter = UV2[TRF] 320; Em. Filter = APC 665; 2nd Em. Filter = Europium 615; Measurement h = 6.5; Ex. light (%) = 100; Delay = 60 s; Window t = 100 us; No. Seq. windows = 1; Time between flashes = 2000us; No. of flashes = 100; No. of flashes for 2nd detector = 100; Calculation: "Ratio Ch1/Ch2"
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10.
PhenotypePotencyEfficacyAnalysis Commentdonor-Activity_Scoredonor-Curve_Descriptiondonor-Fit_LogAC50donor-Fit_HillSlopedonor-Fit_R2donor-Fit_InfiniteActivitydonor-Fit_ZeroActivitydonor-Fit_CurveClassdonor-Excluded_Pointsdonor-Max_Responsedonor-Activity at 0.00245 uMdonor-Activity at 0.012 uMdonor-Activity at 0.061 uMdonor-Activity at 0.307 uMdonor-Activity at 1.530 uMdonor-Activity at 7.660 uMdonor-Activity at 38.30 uMacceptor-Activity_Scoreacceptor-Curve_Descriptionacceptor-Fit_LogAC50acceptor-Fit_HillSlopeacceptor-Fit_R2acceptor-Fit_InfiniteActivityacceptor-Fit_ZeroActivityacceptor-Fit_CurveClassacceptor-Excluded_Pointsacceptor-Max_Responseacceptor-Activity at 0.00245 uMacceptor-Activity at 0.012 uMacceptor-Activity at 0.061 uMacceptor-Activity at 0.307 uMacceptor-Activity at 1.530 uMacceptor-Activity at 7.660 uMacceptor-Activity at 38.30 uMratio-Activity_Scoreratio-Curve_Descriptionratio-Fit_LogAC50ratio-Fit_HillSloperatio-Fit_R2ratio-Fit_InfiniteActivityratio-Fit_ZeroActivityratio-Fit_CurveClassratio-Excluded_Pointsratio-Max_Responseratio-Activity at 0.00245 uMratio-Activity at 0.012 uM
Inconclusive13.091834.236810Partial curve; partial efficacy-4.8830.90.9842-34.23680-2.20 0 0 0 0 0 0-25.614-1.39311.03720.2461-0.3036-5.7242-11.5938-25.6140-5.2831.75290.98-13.72840.540 0 0 0 0 0 0-13.5236-0.10780.6437-0.97941.524-1.1778-8.8692-13.523610Single point of activity-4.7332.04370.938429.5-1.68530 0 0 0 0 0 023.5573-0.471-6.8208
Inactive0-4.5334.95490.9067-8.498040 0 0 0 0 0 0-6.665-0.6313-1.0526-0.74891.2871-0.15130.0555-6.6650-4.5834.95490.8288-9.95180.540 0 0 0 0 0 0-8.7098-1.3652-0.4131-0.32812.6788-0.35192.6278-8.709800041.006611.01792.366
Inactive00041.08160.55511.35950.30851.06552.17941.12591.08160004-0.0963-0.2450.08910.62470.6342-0.494-0.5578-0.09630-5.9830.80.4311-5.8712-240 0 0 0 0 0 0-5.726-4.81040.1768
Inactive00041.1549-0.1524-0.45110.47073.38251.12381.93911.15490-4.4834.95490.89377-0.45540 0 0 0 0 0 04.5418-1.08770.2594-0.10460.25560.1408-1.21254.54180-7.0834.95490.616-2.36631.540 0 0 0 0 0 13.51370.04232.6162
Inconclusive18.492750.517610Partial curve; high efficacy-4.7331.37230.9765-55.0199-4.5023-2.10 0 0 0 0 0 0-41.6818-3.6602-3.5871-2.5019-5.0759-10.5048-14.6077-41.68180Partial curve; partial efficacy-4.6831.55790.9725-36.6133-1.5941-2.20 0 0 0 0 0 0-27.1777-0.0784-0.7494-1.0317-1.2353-5.6071-7.3551-27.177710Partial curve; high efficacy-4.7332.12110.963646.40561.86242.10 0 0 0 0 0 038.6329-0.03154.5997
Inactive0-6.6834.95490.7361-1.28652.540 0 0 0 0 0 0-1.39321.32791.07414.5041-0.7018-0.8755-1.9054-1.39320-4.5834.95490.5552-9.75940.540 0 0 0 0 0 0-8.5495-0.7153-5.84332.74342.73091.20692.3938-8.54950-6.6334.95490.4598-2.53210.540 0 0 0 0 0 11.9741-2.28022.1006
Inconclusive26.121615.491610Single point of activity-4.5834.95490.577-17.4916-2-30 0 0 0 0 0 0-15.4097-6.9974-6.0908-6.42242.0598-1.42642.6002-15.40970-4.5834.95490.6693-13.5584-140 0 0 0 0 0 0-12.132-5.6568-4.2813-0.38510.62280.23462.8137-12.13200045.3420.79440.1149
Inconclusive26.121617.812610Single point of activity-4.5834.95490.6878-19.3126-1.5-30 0 0 0 0 0 0-16.9272-10.04781.6971-0.0428-1.6262-0.17290.6047-16.92720-4.5834.95490.804-15.773-1.540 0 0 0 0 0 0-13.9775-4.9316-2.0861-1.0944-3.58082.08170.1752-13.977500040.36688.0535-0.81
Inconclusive9.268360.548610Partial curve; high efficacy-5.0331.88510.9893-59.9830.5655-2.10 0 0 0 0 0 0-55.2902-1.2407-2.2771-0.06424.05460.7564-24.0285-55.29020Partial curve; high efficacy-4.7831.75290.9955-47.92970.4255-2.10 0 0 0 0 0 0-38.8331-0.4214-0.45151.31221.9121-1.3651-9.8-38.833110Partial curve; high efficacy-4.9831.46410.982851.44262.99242.10 0 0 0 0 0 045.31720.31914.9005
Inactive0-8.5330.40.64651-6.518940 0 0 0 0 0 01.0082-3.76580.1933-2.0113-0.73721.51290.60471.008200040.9276-2.08721.3354-0.3994-0.3692-0.50212.75690.92760-6.8332.72020.54541.4286840 0 0 0 0 0 0-1.46988.09157.2694
Inactive0-5.9834.95490.48791.5-5.767740 0 0 0 0 0 01.6315-0.8707-1.0741-10.6398-10.25010.69161.60551.631500040.2319-0.72510.4323-1.2694-0.66731.60482.18520.231900040.97880.01432.0417
Inactive00041.1366-0.0653-1.3534-0.96291.8213-0.1729-1.35531.13660004-1.05061.52870.86460.6276-0.41651.64232.0654-1.050600042.48044.26523.2543
Inactive00043.17140.45711.41781.3587-2.320.58351.56383.171400040.05460.20581.9406-0.934-1.3299-0.33320.47950.05460-4.5334.95490.867120.898740 0 0 0 0 0 09.76670.83532.1151
Inactive00040.25662.13321.5897-0.9422-0.0645-1.18-0.49270.256600042.29491.5581-1.5672-0.1141-0.41182.6653-0.13372.29490-7.5834.95490.484-5.9211140 0 0 0 0 0 11.5010.40271.2167
Inactive0-4.8833.62720.988-8.18461.540 0 0 0 0 0 0-8.07050.87071.61121.42291.7910.86450.3545-8.070500040.1599-0.22540.38431.0271.5524-0.13610.44260.15990-4.6831.64360.732710-1.481240 0 0 0 0 0 06.8629-0.328-0.3274
Inactive0004-0.552.89132.50730.3210.0886-1.6143-0.4011-0.550004-0.43681.0844-0.4035-0.0903-3.3278-2.9446-3.165-0.436800041.32112.5082-0.6505
Inactive0004-0.40260.69661.28160.3745-1.1709-0.16621.0217-0.402600040.69632.02841.662-1.25520.8424-0.2769-1.8210.69630-5.9334.95490.8972-7.0254-0.540 0 0 0 0 0 11.41420.1606-1.3052
Inactive0-4.5834.95490.4953-9.962-140 0 0 0 0 0 0-8.7183-0.0348-5.636501.3914-4.58231.9354-8.71830-4.5831.27160.8633-8.1513040 0 0 0 0 0 0-5.1261-0.2941.23930.1046-0.8971-1.1027-0.9635-5.12610-5.3332.63840.8011-12.87351.540 0 0 0 0 0 15.2301-0.92495.8913
Inactive00042.9567-0.0435-0.8942-1.35841.60580.19823.19892.956700041.27370.84270.91270.97941.20211.6517-0.11531.27370-5.1834.95490.3473-6.0753140 0 0 0 0 0 12.32272.4164-2.4774
Inactive0-8.4834.50450.7046-0.14056.540 0 0 0 0 0 01.02665.0936-0.42961.5299-0.3418-0.4982-2.61711.02660-7.3834.95490.53740.5-5.597740 0 0 0 0 0 1-2.9506-1.0779-10.0814-0.30431.666-0.12050.3923-2.95060-4.7832.95230.523-5.7344040 0 0 0 0 0 0-5.19540.15072.5032
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1158_MLP
Protocol: A 5 mL overnight pre-culture of E. coli is started by inoculating a tube of lysogeny broth with a single colony from an agar plate. The tube is incubated at 37 degrees C overnight with shaking. The resulting saturated culture is removed from the shaker and diluted into fresh lysogeny broth at 1:100 proportion and incubated at 37 degrees C with shaking for two hours. The culture is removed from the shaker and absorbance is measured at 600 nm. The culture is diluted into fresh lysogeny broth to an estimated absorbance of 0.0002. For each library plate to be screened, two 384-well assay plates are filled with 30 microL per well of fresh lysogeny broth, except for the positive control columns, which are left empty. The multiple of two is necessary to expose the strain in duplicate to the same compounds from a given library plate.

300 nL of experimental compounds are transferred into the assay plates from library plates using a robotically manipulated stainless steel pin array, exposing the strain to the same compounds at the same concentration. The positive control columns are filled with 30 microL of the positive control compound in LB. Thirty microL of E. coli culture at absorbance of 0.0002 are then added to the assay plates, producing a total volume of 60 microL in each well. Plates are incubated at 37 degrees C without shaking and with humidification for 23 hours. The plates are removed from the incubator, and absorbance of the cultures is measured at 600 nm using a PerkinElmer EnVision plate reader. The absorbance is used as the readout.

Positive control: (R)-4-(4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide was present at 0.0754 microM in all wells of column 24.

Negative control: No treatment in remaining empty wells of the assay plate (minimally, wells in column 23).
Comment: A threshold constant was calculated by subtracting 3.6 X experimental well standard deviation for absorbance from the experimental well average absorbance, combining all plates in a screening run. Well absorbance was then subtracted from this threshold value. Wells were considered active if the resulting value after subtracting the threshold constant > 0 for at least one replicate. Activity scores were calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_AAbsorbance_BAbsorbance_AvgThreshold-Absorbance_AThreshold-Absorbance_B
0.7180.7170.7175-0.187986-0.186986
0.7320.720.726-0.201986-0.189986
0.6630.7090.686-0.132986-0.178986
0.6310.6880.6595-0.100986-0.157986
0.6840.6970.6905-0.153986-0.166986
0.7010.7060.7035-0.170986-0.175986
0.6950.6860.6905-0.164986-0.155986
0.6690.6990.684-0.138986-0.168986
0.650.7090.6795-0.119986-0.178986
0.6880.6750.6815-0.157986-0.144986
0.6770.6920.6845-0.146986-0.161986
0.660.7130.6865-0.129986-0.182986
0.6970.6830.69-0.166986-0.152986
0.6540.7120.683-0.123986-0.181986
0.6820.6840.683-0.151986-0.153986
0.6870.7060.6965-0.156986-0.175986
0.6680.6950.6815-0.137986-0.164986
0.70.7040.702-0.169986-0.173986
0.680.7030.6915-0.149986-0.172986
0.690.6870.6885-0.159986-0.156986
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC756
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-7.86374.95490.4691-10.890740 0 0 0 0 0 0 08.2951-3.5934-17.82563.728-3.3143-3.1544-3.41174.3528.2951QC'd by EnamineInactive0-5.91374.95490.48948.51.175740 0 0 0 0 0 0 08.48355.7-2.2368
Inactive0-7.21374.95490.40832.5-6.308740 0 0 0 0 0 0 1-10.1762-3.3308-8.1739-6.92184.266411.9083-0.5284-5.8356-10.1762QC'd by EnamineInactive0-7.21374.95490.3691-6.9367-1.540 0 0 0 0 0 0 0-5.5669-7.1362-0.1385
Inhibitor1.9331113.210487Complete curve; high efficacy-5.71374.95490.9846-123.2827-10.0723-1.10 0 0 0 0 0 0 0-117.206-10.7699-22.4888-12.4254-6.51180.6162-122.7414-125.2872-117.206QC'd by EnamineInhibitor1.9331120.518410Complete curve; high efficacy; poor fit-5.71374.95490.9442-119.760.7584-1.31 0 0 0 0 0 0 0-113.3163-116.2959-15.8547
Inactive0-8.81374.95490.6276-1.5-23.330940 0 0 0 0 0 0 0-6.9561-18.60914.2346-0.05635.7534-2.7207-6.6784-4.0458-6.9561QC'd by EnamineInactive0-4.91374.95490.67133-13.282940 0 0 0 0 0 0 1-8.9666-10.8624-14.0596
Inhibitor48.557734.128310Partial curve; partial efficacy; poor fit-4.31371.59360.9877-48.5369-14.4086-2.40 0 0 0 0 0 0 0-39.4219-12.8405-14.8776-15.1051-14.86-12.8749-15.8706-20.1132-39.4219QC'd by SIGMAInhibitor68.589642.307610Single point of activity-4.16373.990.6044-42.24050.0671-30 0 0 0 0 0 0 0-32.3397-15.868116.9894
Inactive0-7.96374.95490.741.5-10.355940 0 0 0 0 0 0 1-15.0169-9.9531-10.71334.5939-1.7304-1.45467.6602-0.5767-15.0169QC'd by SIGMAInactive0004-14.859-13.2163-9.3098
Inactive0-6.51374.95490.59899-2.513340 0 0 0 0 0 0 011.69730.78462.1119-10.0111-3.685212.17340.718111.618411.6973QC'd by SIGMAInactive040 0 0 0 0 0 0 016.3373-14.8015-9.7381
Inhibitor68.589632.190510Partial curve; partial efficacy; poor fit-4.16374.95490.9333-32.19050-2.40 0 0 0 0 0 0 0-25.9921-0.75610.9798-0.51641.0571-2.5971-2.18895.2808-25.9921QC'd by SIGMAInhibitor54.482738.551110Single point of activity-4.26373.67720.7506-35.47323.0779-30 0 0 0 0 0 0 0-30.5241-3.270317.9183
Activator7.695932.09880Complete curve; partial efficacy; poor fit-5.11371.17050.89385.5-26.59881.40 0 0 0 0 0 0 03.0626-32.5823-21.1084-29.0917-26.3315-18.7973-20.4148-1.32993.0626QC'd by SIGMAInactive0-7.46374.50450.4143-10.33733.540 0 0 0 0 0 0 17.47462.66914.4156
Inactive0-8.81374.44950.581.039522.540 0 0 0 0 0 0 119.8217.5365-0.7335-0.826912.2606-2.48681.3946-4.133719.82QC'd by SIGMAInactive00044.4393-3.40321.9365
Activator9.688587.44380Partial curve; high efficacy-5.01371.1110.9835.4518-51.99212.10 0 0 0 0 0 0 031.4522-53.6971-45.0647-53.1956-58.3066-41.7857-30.32154.685831.4522QC'd by SIGMAActivator24.3365131.06770Partial curve; high efficacy-4.61371.13410.970482.8838-48.18392.10 0 0 0 0 0 0 060.7185-41.9229-50.2592
Inhibitor68.5896102.999410Single point of activity-4.16374.95490.9126-112.465-9.4656-30 0 0 0 0 0 0 0-93.2546-12.8632-27.0848-7.3454-8.8555-9.7568-7.97886.4016-93.2546QC'd by SIGMAInhibitor68.589685.608410Single point of activity-4.16374.95490.944-101.5037-15.8953-30 0 0 0 0 0 0 0-85.4409-16.1487-18.1915
Inhibitor21.689934.032910Partial curve; partial efficacy; poor fit-4.66371.47870.8531-36.5329-2.5-2.40 0 1 0 0 0 0 0-32.94412.3801-9.142323.5287-7.26264.059-6.3199-16.9462-32.9441QC'd by SIGMAInactive0-4.76373.92950.9033-24.5486040 0 0 0 0 0 0 0-24.62381.1616-5.4271
Inactive0-8.36370.60.5758-5.19734.497140 0 0 0 0 0 0 0-1.492426.08197.16867.27432.4662-0.9291-23.91225.1445-1.4924QC'd by SIGMAInactive0-6.06372.40640.6203-9.38677.540 0 1 0 0 0 0 1-0.299213.05514.9918
Inactive0-8.81374.95490.7618-4.635640 0 0 0 0 0 0 10.89323.8508-8.0292-4.7013-4.9681-1.7031-4.6863-4.9470.8932QC'd by SIGMAInactive0-6.16373.92950.60363-4.918140 0 0 0 0 0 0 1-8.3052-1.6572-3.0816
Activator9.6885153.03170Complete curve; high efficacy-5.01372.95230.9881152.6925-0.33921.10 0 0 0 0 0 0 0154.2348-8.4111-10.58393.4205-1.171512.040612.3376130.2412154.2348QC'd by SIGMAActivator13.6854129.32160Complete curve; high efficacy-4.86374.95490.9964137.38078.0591.11 0 0 0 0 0 0 0137.932449.111113.295
Inactive0-4.91374.95490.444-12.5490.540 0 0 0 0 0 0 15.8614-0.0331-9.32676.6938-0.25312.49384.0461-11.29095.8614QC'd by LightBiologicalsInactive0004-2.7991-4.8479-7.8846
Activator24.336541.70840Single point of activity-4.61374.0950.931932.657-9.051430 0 0 0 0 0 0 032.0784-3.5663-7.3386-15.2356-4.8834-11.4699-12.65141.923932.0784QC'd by SIGMAActivator48.557746.25170Single point of activity-4.31374.95490.885537.4014-8.850230 0 0 0 0 0 0 035.5314-6.6661-5.471
Activator6.1131159.82730Complete curve; high efficacy-5.21372.53340.9773152.783-7.04431.10 0 0 0 0 0 0 0153.3966-25.2204-14.08523.3931-8.592911.330526.7308143.426153.3966QC'd by SIGMAActivator24.336560.25150Partial curve; high efficacy; poor fit-4.61374.0950.6456118.703558.45192.30 0 0 0 0 0 0 0117.761480.334882.544
Inhibitor1.722939.472922Partial curve; partial efficacy-5.76371.41630.986-34.97294.5-2.20 0 0 0 0 0 0 14.48376.73975.89010.58273.8988-4.4773-25.2126-33.31084.4837QC'd by SIGMAInhibitor6.85939.386121Partial curve; partial efficacy-5.16370.80.943-41.2694-1.8833-2.20 0 0 0 0 0 0 18.8427-1.1528-2.3725
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:SIRPalphatyrosine-protein phosphatase non-receptor type substrate 1 isoform 1 precursor [Homo sapiens]
External ID: adst-pstx-s1-alphascreen-lopac-o1
Protocol: PROTOCOL TABLE (as described by Miller, T. et al. 2019)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1a. Reagent. 2 uL SIRPalpha-biotin (25 nM) added to respective wells in Assay buffer; white/solid bottom high base, med bind 1536-well plates (Greiner 789075)
1b. Reagent. 2 uL Assay buffer negative control for background fluorescence
2. Reagent. 23 nL library compounds (7-pt, 1:4 intraplate titration series) or DMSO control transferred by Pin Tool
3. Centrifuge. Centrifuge plate for 30 s at 1000 RPM
4. Incubation.#Incubate reagents at room temperature for 30 min, protected from light
5. Reagent. 2 uL CD47-His (12.5 nM) in Assay buffer
6. Centrifuge. Centrifuge plate for 30 s at 1000 RPM
7. Incubation.#Incubate reagents at room temperature for 30 min, protected from light
8. Reagent. 1 uL Ni-NTA beads (10 ug/mL) added to respective wells
9. Reagent. 1 uL SAV beads (10 ug/mL) added to respective wells
10. Centrifuge. Centrifuge plate for 30 s at 1000 RPM
11. Incubation. Incubate reagents at room temperature for 30 min, protected from light
12. Detector. Measure AlphaScree n on EnVision (1536A1 aperture)

Notes
Where possible, perform Donor bead dilution and addition away from direct sunlight or with bright overhead lights turned off (<100 lux, similar to hallway lighting). Lighting should still be bright enough to allow accurate pipetting.

1. Assay buffer composition.#Phosphate buffered saline (PBS; 10 mM Phosphate, 137 mM NaCl, and 2.7 mM KCl; pH 7.4), 0.05% IGEPAL CA-630

2. 23nL of LOPAC128 library compounds (7 plates) or DMSO vehicle control transferred to 9 Greiner white/solid bottom high base, TC plates in 7 interplate 1:5 titrations (see Yasgar, A. et al. 2008) with Pintool. Two of the 9 plates are DMSO-only in compound field at beginning and end of compound library-treated plates.

12. Aperture = 1536 plate HTS AlphaScreen; plate-detector distance = 0; Total measurement time = 240; Ex. time = 80 ms (33%); Afterglow CT1 corr. factor = 0; Glow CT2 corr. factor = 0; Bleach CT3 corr. factor = 0; Ref. signal= 417733; Ref. AD gain = 2
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with an activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For activity.curve_class == -1.2 && abs(activity.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For activity.curve_class == -2.1 || ( activity.curve_class==-2.2 && abs(activity.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For activity.curve_class == -1.2 || activity.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20).
PhenotypePotencyEfficacyAnalysis Commentactivity-Activity_Scoreactivity-Curve_Descriptionactivity-Fit_LogAC50activity-Fit_HillSlopeactivity-Fit_R2activity-Fit_InfiniteActivityactivity-Fit_ZeroActivityactivity-Fit_CurveClassactivity-Excluded_Pointsactivity-Max_Responseactivity-Activity at 0.00245 uMactivity-Activity at 0.012 uMactivity-Activity at 0.061 uMactivity-Activity at 0.307 uMactivity-Activity at 1.530 uMactivity-Activity at 7.660 uMactivity-Activity at 38.30 uMCompound QC
Inactive0004-4.0917-3.7354-4.8430.0144-1.5810.22220.7129-4.0917QC'd by SigmaAldrich
Inactive0004-1.8119-4.6457-2.98290.2607-5.1396-4.5076-0.2191-1.8119QC'd by SigmaAldrich
Inactive0004-3.29080.89310.51490.15820.29240.0542-0.9744-3.2908QC'd by SigmaAldrich
Inactive0004-1.0691-0.4274-0.59222.593-1.3363.21771.6717-1.0691QC'd by SigmaAldrich
Inactive0004-2.7744-2.33830.6451-1.6164-0.85760.1691.7776-2.7744QC'd by SigmaAldrich
Inactive000400000000QC'd by SIGMA
Inactive0004-0.2538-0.70582.0769-1.4287-0.1919-1.0207-0.0558-0.2538QC'd by SIGMA
Inactive0004-1.80450.93635.5323-1.0883-0.90613.3994-2.6869-1.8045QC'd by SIGMA
Inactive0004-0.1389-5.2345-1.1790.66690.18041.03551.009-0.1389QC'd by SIGMA
Inactive00044.47936.2562-0.5716.56125.1993.8996.00564.4793QC'd by SIGMA
Inactive00043.45644.7581-2.90652.16615.50112.21862.61393.4564QC'd by SIGMA
Inactive00045.0215-2.3758-0.79986.8713-2.50636.83294.33165.0215QC'd by SIGMA
Inactive00047.76633.51947.1426.20625.53263.71734.72167.7663QC'd by SIGMA
Inactive0004-0.5845-0.2976-0.5243.011-0.4112.59550.1424-0.5845QC'd by SIGMA
Inactive00043.69993.6442-1.18483.5502-2.13713.29042.99513.6999QC'd by SIGMA
Inactive00042.56115.70561.48540.24920.4351-0.44690.92512.5611QC'd by SIGMA
Inactive00047.0126-0.677-1.3105-1.5745-2.5386-0.58270.21037.0126QC'd by SIGMA
Inactive0-4.7333.62720.9895-20.1019-0.540 0 0 0 0 0 0-18.8349-1.2868-1.6869-0.66860.444-0.5195-1.2347-18.8349QC'd by SIGMA
Inactive0-4.8330.80.8672-14.67651.540 0 0 0 0 0 0-10.56384.46760.00420.7775-0.7402-1.4572-3.0948-10.5638QC'd by SIGMA
Inactive000400000000QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: MTASE-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; SMMTase Enzyme (2x) in reaction buffer, columns 1- 48.
2; Reagent; 1 uL; SAM (4x) in reaction buffer, columns 1-48.
3; Controls; 23 nL; DMSO in column 4; sinefungin in DMSO (0 uM - 40 uM) in 7-point 1:2 dilution series (n = 2) in column 2.
4; Compounds; 23 nL; Columns 5-48.
5; Reagent; 1 uL; Substrate (4x) in reaction buffer, columns 2-48.
6; Time; 20-30 min; Incubation.
7; Reagent; 1 uL; MTase-Glo reagent (5X), columns 1-48.
8; Time; 30 min; Incubation.
9; Reagent; 5 uL; MTase-Glo Detection reagent, columns 1-48.
10; Time; 30 min; Incubation, luminescence evolution.
11; Detection; Luminescence; ViewLux uHTS Microplate Imager (PerkinElmer).

NOTES (numbers refer to Sequence numbers above)
1, 2, 5. White Medium Binding Greiner 1536-well plates (Cat #789175-F, Greiner Bio-One, Monroe, NC); Reaction buffer: 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA. Evaporation was prevented by covering assay plates with metal lids containing holes to allow gas diffusion.
1. Six SMMTase were profiled: HNMT, GNMT, PNMT, COMT, NNMT, GAMT
2. The corresponding SAM cofactor concentration was used for each SMMTase: HNMT - 9.3 uM SAM; GNMT - 12.1 uM SAM; PNMT - 3.6 uM SAM; COMT - 14.5 uM SAM; NNMT 11.9 uM SAM; GAMT - 5.6 uM SAM.
3, 4. Pintool transfer
5. The corresponding substrate was used for each enzyme: HNMT - 5.3 uM Histamine; GNMT - >500 uM Glycine; PNMT - 16.2 uM Norephinephrine; COMT - 13.7 uM Norephinephrine; NNMT - 3.8 uM Nicotinamide; GAMT - 2.5 uM Guanidinoacetate.6, 8, 10. Room temperature
6. Final reaction conditions: 10 nM COMT, 5 uM SAM, 15 uM norepinephrine, 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA; refer to tables 2 and S1 for specific timing.
8. Conversion of SAH to ADP; MTase Glo Kit (Promega, Madison, WI).
10. Conversion of ADP to ATP and detection by UltraGlo luciferase; MTase Glo Kit (Promega, Madison, WI).
11. Settings: 20 s exposure, 1X binning, high gain, medium speed.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are assayed at single point activity (40 uM).
2. Active / Inactive compound calling is based on the results of the enzyme assay panel. ACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 50 and are compounds that have <= -50% max response in ANY ONE of the six enzymes. INACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 0 and are those that have >= -30% max response in ALL SIX enzymes. The remaining compounds are INCONCLUSIVE and have PUBCHEM_ACITIVITY_SCORE = 30.
COMT-Max_ResponseGAMT-Max_ResponseGNMT-Max_ResponseHNMT-Max_ResponseNNMT-Max_ResponsePNMT-Max_Response
-14.477-0.906-64.36-7.723-13.221-6.568
-97.283-96.83-99.246-99.097
-11.662-7.108-69.542-15.105-18.57-11.209
9.957-8.37-63.807-27.029-13.633-0.512
-1.3788.081-1.801-70.001-9.255-2.174
-4.184-8.838-45.186-20.976-17.93-50.762
-64.186-17.487-82.517-23.323-14.889-4.424
-28.27-13.82-44.132-13.042-22.645-61.981
-95.9186.395-70.158.26-8.601-15.867
-6.366.696-61.41910.286-22.134-20.539
2.7649.187-5.281.889-50.6463.945
5.467.241-52.1632.748-5.3684.271
18.645-5.1-85.869-4.46517.42
-33.223-8.861-69.978-8.649-22.429-13.542
-22.681-17.904-81.69-53.866-21.453-18.314
3.649-5.536-6.193-64.526-18.858-7.356
-17.938-19.922-61.7-32.188-41.884-42.419
-0.0336.8778.069-87.187-3.6082.522
66.24812.293-50.945-8.947-3.8437.458
-0.7140.817-11.379-86.711-10.789-2.627
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: Papain-kebotix-p1-LOPAC
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 3 uL; 4/3x Enzyme solution (working concentration of 5 nM) or 3 uL buffer
2; Compounds; 17 nL; library compounds and controls (working concentration of 169 nM - 10 mM)
3; Time; 15 min; room temperature incubation
4; Reagent; 1 uL; 4x 2 uM Z-FR-AMC substrate
5; Centrifugation; 1000 rpm; 15 sec centrigure
6; Detection; Fluorescence Read 1; ViewLux plate reader
7; Time; 10 min; room temperature incubation
8; Detection; Fluorescence Read 2; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above; values are from representative experiments)
1; Dispense 3 uL of [4/3x] 5 nM Papain-buffer solution in medium-binding black solid-bottom Greiner plates (789176-F); columns 1-2 and 5-43. Dispense 3 uL of assay buffer (100 mM Na-acetate pH 5.5, 5 mM DL-Cysteine, 0.01% Tween20) to columns 3 and 4.
2; Compounds are single pin-transferred (17 nL) for a final concentration range of 0.664 nM - 39.2 uM.
3; Room temperature incubation.
4; Dispense 1 uL of [4x] 2 uM Z-FR-AMC substrate solution into the assay plate, columns 1 - 48.
5; Centrifuge the assay plate to remove bubbles.
6; Initial fluorescence signal (Read 1) is obtained using the Pherastar plate reader equipped with a 340 nm excitation filter; 460 nm emission filter; 10 flashes at 709 gain setting.
7; Room temperature incubation in the dark.
8; Final fluorescence signal (Read 2) is obtained using the Pherastar plate reader equipped with a 340 nm excitation filter; 460 nm emission filter; 10 flashes at 709 gain setting.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00803 uMActivity at 0.034 uMActivity at 0.147 uMActivity at 0.632 uMActivity at 2.710 uMActivity at 11.60 uMActivity at 49.80 uMCompound QC
Inhibitor1.12298.412987Complete curve; high efficacy-5.954.95490.9765-91.41297-1.10 0 0 0 0 0 1-2.970320.2543-3.17153.60981.8936-92.6414-89.5154-2.9703QC'd by SigmaAldrich
Inhibitor1.122112.853387Complete curve; high efficacy-5.952.63840.9992-95.353317.5-1.10 0 0 0 0 0 128.712919.89115.857315.7073-1.8936-84.7405-95.85928.7129QC'd by SigmaAldrich
Inhibitor1.12293.006586Complete curve; high efficacy-5.951.92820.9904-76.006517-1.10 0 0 0 0 0 0-71.223923.125215.229210.0814-5.8563-60.8696-80.1154-71.2239QC'd by SigmaAldrich
Inhibitor1.995381.638584Complete curve; high efficacy-5.74.0450.9877-63.638518-1.10 0 0 0 0 0 0-61.529426.956513.151417.951813.5965-45.354-65.3037-61.5294QC'd by SigmaAldrich
Inhibitor3.548194.531644Partial curve; high efficacy-5.451.24750.9701-91.53163-2.10 0 0 0 0 0 0-91.8992-6.2675.74835.561-0.6312-44.3067-66.7841-91.8992QC'd by SIGMA
Inhibitor25.1189867.70544Partial curve; high efficacy-4.61.98870.9975-871.705-4-2.10 0 0 0 0 0 0-695.13950.2725-6.144710.6341-26.2399-30.3641-161.7621-695.1395QC'd by SigmaAldrich
Inhibitor25.1189702.600244Partial curve; high efficacy-4.62.63840.9984-700.60022-2.10 0 0 0 0 0 0-601.89024.8138-14.073316.09762.7953-2.3238-76.8282-601.8902QC'd by SigmaAldrich
Inhibitor15.8489172.091443Partial curve; high efficacy-4.82.40640.9887-171.59140.5-2.10 0 0 0 0 0 0-168.22683.72398.32510.0976-11.81240.3098-56.0352-168.2268QC'd by SigmaAldrich
Inhibitor7.943390.973943Partial curve; high efficacy-5.11.46410.9846-94.9739-4-2.10 0 0 0 0 0 0-87.9388-8.08363.3697-4.3902-11.0911-16.5763-64.141-87.9388QC'd by SigmaAldrich
Inhibitor28.1838600.123342Partial curve; high efficacy-4.552.09370.9958-604.1233-4-2.10 0 0 0 0 0 0-463.996411.1717-9.1179-13.1707-14.5176-24.6321-87.7533-463.9964QC'd by SIGMA
Inhibitor25.1189300.09742Partial curve; high efficacy-4.62.30310.9942-302.097-2-2.10 0 0 0 0 0 0-250.495-2.99731.18936.9268-16.321-1.2393-45.2863-250.495QC'd by SIGMA
Inhibitor14.1254117.995442Partial curve; high efficacy-4.853.06540.972-106.495411.5-2.10 0 0 0 0 0 0-104.50053.54227.3344.585421.009921.5337-30.4846-104.5005QC'd by SigmaAldrich
Inhibitor8.912590.275242Partial curve; high efficacy-5.051.50950.9138-86.77523.5-2.10 0 0 0 0 0 0-80.8586-10.02793.80581.64821.6917-16.5684-48.3456-80.8586QC'd by SigmaAldrich
Inhibitor25.1189345.20342Partial curve; high efficacy-4.63.57220.9994-338.7036.5-2.10 0 0 0 0 0 0-311.881210.26340.99116.53669.10735.4222-14.2731-311.8812QC'd by SigmaAldrich
Inhibitor28.1838850.155942Partial curve; high efficacy-4.552.63840.9989-854.1559-4-2.10 0 0 0 0 0 0-697.83989.7184-0.3964-12-9.8287-16.4214-83.1718-697.8398QC'd by SigmaAldrich
Inhibitor22.3872292.26642Partial curve; high efficacy-4.651.69240.9891-289.7662.5-2.10 0 0 0 0 0 0-229.9732.4523-15.460913.36599.468-6.1967-69.7797-229.973QC'd by SigmaAldrich
Inhibitor28.1838722.363242Partial curve; high efficacy-4.552.35310.999-721.86320.5-2.10 0 0 0 0 0 0-572.9073-0.81748.7215-7.512210.1894-8.6754-80-572.9073QC'd by SigmaAldrich
Inhibitor25.1189315.115242Partial curve; high efficacy-4.62.84730.998-326.7267-11.6115-2.10 0 0 0 0 0 0-288.1188-7.1753-6.3429-15.9024-19.2065-9.7599-43.5242-288.1188QC'd by SigmaAldrich
Inhibitor22.3872108.159741Partial curve; high efficacy-4.652.09370.9862-96.659711.5-2.10 0 0 0 0 0 0-79.582117.03024.674310.14415.49849.1097-10.2994-79.5821QC'd by SIGMA
Inhibitor12.589374.198941Partial curve; partial efficacy-4.93.1320.961-69.19895-2.20 0 0 0 0 0 0-67.77688.08364.16257.5122-6.402211.1541-28.8987-67.7768QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:1102 靶标:NS3 [Hepatitis C virus]
External ID: 20130523FPNS3DALOPAC
Protocol: Assay Overview:

The purpose of this biochemical assay is to determine the ability of compounds in Sigma-Aldrich's Library of Pharmacologically Active Compounds (LOPAC1280) to displace the hepatitis C non-structural protein 3 helicase (NS3h) from its substrate oligonucleotide. In this biochemical assay, the fluorescence polarization of a single strand of DNA with a 5' Cy5 fluorophore (Cy5-dT15) incubated with NS3h and test compound is monitored. Fluorescence polarization increases when NS3h binds the substrate. As designed, compounds that interfere with binding decrease the fluorescence polarization.

Protocol Summary:

Assays were performed in 20 uL in 384-well black small-volume microplates. All assays contained 5 nM Cy5-dT15 DNA (5'- Cy5 TT TTT TTT TTT TTT T -3'), 15 nM NS3h, 25 mM MOPS, pH 7.5, 1.25 mM MgCl2, 0.0025 mg/ml BSA, 0.005% (v/v) Tween 20, and 0.025 mM DTT. Compounds dissolved in DMSO were added at final concentration of 0.1mM and a final DMSO concentration of 1% (v/v). Cy5 fluorescence polarization was read using a G-factor calculated from a well lacking NS3h or test compounds. Percent inhibition was calculated according to the equation below.

%_Inhibition = 100 - ( ( Fc - F[+]) / (F[-] - F[+] ) ) * 100

Where:

Fc is the fluorescence polarization in the presence of the compound
F[-] is the average fluorescence polarization of no enzyme negative controls
F[+] is the average fluorescence polarization of positive controls (200 nM dT20).

Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter. Any compound that exhibited greater percent inhibition than the cutoff parameter was considered active.

List of Reagents:

Cy5-dT15 (Integrated DNA Technologies Inc, custom synthesized)
dT20 (Integrated DNA Technologies Inc, custom synthesized)
MOPS (Fisher Scientific, part BP308-100)
Magnesium Chloride (Fisher Scientific, part BP214-500)
384-well plates (Greiner Bio-One, black, part 784076)
Comment: The assay was performed and submitted by the Frick Lab at the University of Wisconsin-Milwaukee. The compounds tested in this assay were from Sigma-Aldrich's LOPAC-1280 set.
HDA (HCV NS3h) % Inhibition
119
100
96
96
91
86
58
43
41
37
36
22
19
13
12
11
8
8
6
6
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:26908 靶标:N/A
External ID: HTS97080
Protocol: 96-well plates were coated with 100 microl of 0.25 mg/ml biotin conjugated-gelatin overnight and then washed twice with PBS. Endothelial cells (3 x 104) were plated in pericyte-conditioned medium and the cells were grown to confluence for 6 days followed by the treatment with compounds for 24 h. On day seven, 6 microg/ml of NeutrAvidin TM, FITC conjugate (FITC-avidin, 60 kDa) (Thermo Fisher Scientific) was added to cells for 3 min. The cells were washed twice with PBS to remove the unbound FITC-avidin. Wells were filled with 100 microl of PBS and bound FITC-avidin fluorescence was measured using plate reader with wavelengths of 492 nm. The fluorescence units of cells treated with compounds were normalized to values of cells treated with vehicle (DMSO) and presented as average with standard deviation.
Comment: Measuring the fluorescence of FITC-avidin that has penetrated the endothelial monolayer and bound to a biotinylated gelatin-coated plate can be used as a surrogate parameter for endothelial permeability. Here we show the average FITC-avidin fluorescence of drug-treated cells as fold of vehicle-treated cells. Compounds causing 0.3-fold or higher fluorescence changes are considered active, while compounds causing changes of less than 0.3-fold are considered inactive.
Average (-fold FITC-avidin fluorescence normalized to DMSO)Standard DeviationCHEMICAL NAME
1.40.03Phenserine
0.80.04Felbamate
0.80.09Fusaric acid
1.30.01Flunarizine dihydrochloride
1.20.05cis-(Z)-Flupenthixol dihydrochloride
0.90.11L-Glutamic acid hydrochloride
10.19GW7647
1.20.05Ellipticine
0.70.03Ethosuximide
0.80N-Methyl-beta-carboline-3-carboxamide
10.02Fusidic acid sodium
0.80.02Furosemide
0.80.055-Fluorouracil
0.80.015-fluoro-5'-deoxyuridine
0.70Furafylline
0.80.04Ganciclovir
0.90.05NS5806
0.70.02RepSox
1.10.04Nitidine chloride
1.20.14SGC-AAK1-1N
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:1102 靶标:N/A
External ID: 20130620FPNS3INTERFERELOPAC
Protocol: Assay Overview:

The purpose of this biochemical assay is to determine the ability of compounds in Sigma-Aldrich's Library of Pharmacologically Active Compounds (LOPAC1280) to enhance or quench the fluorescence intensity of a Cy5-labeled substrate oligonucleotide bound to the hepatitis C non-structural protein 3 helicase (NS3h).
In this biochemical assay, the fluorescence of a single strand of DNA with a 5' Cy5 fluorophore (Cy5-dT15) incubated with NS3h and test compound is monitored.

Protocol Summary:

Assays were performed in 20 uL in 384-well black small-volume microplates. All assays contained 5 nM Cy5-dT15 DNA (5'- Cy5 TT TTT TTT TTT TTT T -3'), 15 nM NS3h, 25 mM MOPS, pH 7.5, 1.25 mM MgCl2, 0.0025 mg/ml BSA, 0.005% (v/v) Tween 20, and 0.025 mM DTT. Compounds dissolved in DMSO were added at final concentration of 0.1mM and a final DMSO concentration of 1% (v/v). Cy5 fluorescence was read. Interference was calculated according to the equation below.

Interference = Fc / F[-]

Where:

Fc is the fluorescence in the presence of the compound
F[-] is the average fluorescence of negative controls

Any compound that exhibited an interference value greater than 0.8 or less than 1.2 was considered inactive. Any compound that exhibited an interference value greater than or equal to 1.2 was considered active (a fluorescent enhancer) in the assay and will not be pursued further. Any compound that exhibited an interference value less than or equal to 0.8 was considered active (a fluorescent quencher) in the assay and will not be pursued further.

List of Reagents:

Cy5-dT15 (Integrated DNA Technologies Inc, custom synthesized)
dT20 (Integrated DNA Technologies Inc, custom synthesized)
MOPS (Fisher Scientific, part BP308-100)
Magnesium Chloride (Fisher Scientific, part BP214-500)
384-well plates (Greiner Bio-One, black, part 784076)
Comment: The assay was performed and submitted by the Frick Lab at the University of Wisconsin-Milwaukee. The compounds tested in this assay were from Sigma-Aldrich's LOPAC-1280 set.
HDA (HCV NS3h) Interference
0.6
0.6
0.7
0.8
0.8
0.8
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: ZIK163
Protocol: Assay Protocol Summary:

HEK 293 cells were cultured in EMEM (ATCC, Cat. # 30-2003) medium with 10% fetal bovine serum (GE healthcare Life Sciences, Cat. # SH30071.03), and 1% Pen/Strep (Gibco, Cat. # 15140-122). Cells were seeded in the assay plate and incubated at 37 C with 5% CO2 for 20 hours. Compounds were added to cells and incubated for one hour before addition of ZIKV MR766 strain solution to cells (MOI = 0.5). After an incubation at 37 C for 24 hours, the reagent mixture of TR-FRET ZIKV NS1 assay using two anti-ZIKV NS1 antibodies was added to assay plates. The TR-FRET signals in assay plates were measured using an Envision plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% NS-1) and wells containing ZIKV infected cells as a positive control (100% NS-1 level). The percentage inhibition of NS-1 level by these small molecules were then calculated using a Prism software (n=3) (GraphPad, San Diego, CA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00403 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.042 uMActivity at 0.064 uMActivity at 0.188 uMActivity at 0.368 uMActivity at 0.593 uMActivity at 0.938 uMActivity at 1.786 uMActivity at 4.810 uMActivity at 9.196 uMActivity at 15.34 uMActivity at 20.13 uMActivity at 46.08 uMActivity at 92.78 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-9.02924.95490.57853.5-21.368240 0 0 0 0 0 0 0 0 0 06.1188-14.47353.76344.0707-3.3965-3.24292.11643.0211.203312.80947.72326.1188QC'd by BIOMOL
Inactive0-8.77922.18760.86643-10.761340 0 0 0 0 0 0 0 0 0 1-5.1924-8.5511-1.21672.23634.66112.89612.5191-0.35994.87534.24992.8447-5.1924QC'd by BIOMOL
Inactive0-4.57921.10.6104160.044840 0 0 0 0 0 0 0 0 0 013.51042.1411-2.7054-0.1162-4.96271.3942-0.14943.46892.07474.89631.211613.5104QC'd by BIOMOL
Inhibitor33.173492.406110Single point of activity-4.47924.95490.9926-90.94761.4585-30 0 0 0 0 0 0 0 0 0 0-75.71781.4606-1.3942-0.01662.35683.9170.43154.1664.6971-0.6805-0.2822-75.7178QC'd by BIOMOL
Inactive0004-0.7339-3.29410.34999.447-0.85343.22589.6689-3.1405-0.8022-0.61443.5586-0.7339QC'd by BIOMOL
Inhibitor37.2212126.92610Single point of activity-4.42924.95490.9604-125.84371.0823-30 0 0 0 0 0 0 0 0 0 0-95.33614.9627-11.2531-1.54361.576812.89633.1535-3.28632.10790.59751.7261-95.3361QC'd by BIOMOL
Inactive00043.0978-8.24371.8945-4.0621-5.7518-3.07222.4407-20.34486.73320.80220.66563.0978QC'd by BIOMOL
Inhibitor37.2212122.883910Single point of activity-4.42924.95490.9667-127.2961-4.4122-30 0 0 0 0 0 0 0 0 0 0-96.4364-2.6516-15.5041-3.3271-10.60632.6854-4.1209-5.89430.08440.684-5.7085-96.4364QC'd by BIOMOL
Inactive00043.9568-0.93102.09483.4414-9.1771-0.5819-2.85950.63184.33922.56033.9568QC'd by BIOMOL
Inactive0-5.22924.95490.88138.5-0.736140 0 0 0 0 0 0 0 0 0 12.4420.12-1.3709-0.73690.5141-0.3941-0.5484-3.5301-1.09672.03078.42262.442QC'd by BIOMOL
Inactive0-7.12924.95490.59452-10.367440 0 0 0 0 0 0 0 0 0 1-7.3805-4.7796-12.3628-4.2223-20.7229-6.16453.52982.5502-0.1858-3.17516.2912-7.3805QC'd by BIOMOL
Inactive0004-1.029-4.8963-5.2116-6.0249-6.2241-2.77181.3776-3.834-0.0996-8.3651-2.556-1.029QC'd by BIOMOL
Inhibitor29.565943.826110Single point of activity-4.52924.95490.9504-41.15562.6705-30 0 0 0 0 0 0 0 0 0 0-36.66399.92534.78012.14111.74271.24481.5273.917-0.04980.86310.9129-36.6639QC'd by BIOMOL
Inactive0-5.27923.1320.898918.50.718140 0 0 0 0 0 0 0 0 0 16.8356-1.48494.2243-0.37551.1691-1.21182.8932.3554-0.614410.078517.74196.8356QC'd by BIOMOL
Inactive0-4.42924.95490.7047-36.43965.726840 0 0 0 0 0 0 0 0 0 0-26.65513.57955.16071.12952.3632-4.622117.88017.38491.025210.130312.7889-26.6551QC'd by BIOMOL
Inhibitor37.2212134.712410Single point of activity-4.42924.95490.9951-133.66781.0446-30 0 0 0 1 0 0 0 0 0 0-101.2635-1.94513.1920.1829-1.5628-54.69661.4630.44892.9593-1.03082.6933-101.2635QC'd by BIOMOL
Inactive00041.5963.88457.82812.82895.00760.88670.40531.95913.01471.064-0.99651.596QC'd by BIOMOL
Inactive00043.14620.5630.8445-0.92730.96045.00081.3917.8493.087.5178-2.89783.1462QC'd by BIOMOL
Inactive000412.4682.6028-2.9527-4.74480.75953.652524.0911-1.5192.4407-0.85341.237412.468QC'd by BIOMOL
Inactive0004-2.2017-11.0599-4.6766-7.95360.3755-8.1072-0.4608-0.2731-13.3811-1.9799-5.291-2.2017QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Center for Chemical Genomics, University of Michigan 靶标:
External ID: MScreen:TargetID_600
Protocol: C-terminally 6xHis tagged CDK2/Cyclin A complex and N-terminally Flag tagged CDC25B C473S (372-566) were expressed and purified. Proteins were incubated together at a final concentration of 125 nM each for 1 hr prior to incubation with compound for 1 hr, followed by addition of anti-6xHis europium cryptate donor beads (Cisbio) and anti-Flag XL-665 acceptor beads (Cisbio) at a final dilution of 1:350 for 1 hr. 20mM potassium fluoride was added 10 minute prior to plate reading. Assay reagents were dispensed using a multidrop liquid dispenser (Thermo Scientific) onto uncoated, black, low-volume, 384-well plates (Corning). Assay plates were quantified using an Envision plate reader (Perkin-Elmer) with excitation of the europium crytate donor at 337 nm wavelength and emission of the donor at 620 nm and emission of the XL-665 acceptor at 665 nm in 18 uL volumes. Assays were performed in a buffer containing 50 mM Tris (pH 7.5), 50 mM NaCl, 10mM MgCl2, 1mM TCEP, with addition of and 1mM ATP, 0.05% BSA, and 0.05% Tween-20 immediately prior to the start of the assay.
Comment: The activity outcome is based on a Z-score (number of standard deviations from the negative control mean) of 3 or higher on at least 50% times that the sample was screened.
For instance, if the sample was screened in n=4 runs, it would be considered active only if it had a Z-score of 3 or above in at least 2 runs.

This screen was funded by NIH grant number: R01CA181185
Z_SCORE
0.28
-0.54
-0.02
0.22
0.37
-0.81
-0.26
-0.14
-0.61
-0.44
0.29
0.22
-0.12
-0.13
0.95
-0.29
-0.37
0.17
-0.64
-0.78
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:FH fumarate hydratase [Homo sapiens (human)]
External ID: FUM001
Protocol: Assay Protocol Summary:

For primary high-throughput screen, 3 ul of FH solution (containing 13.33nM human fumarate hydratase, 13.33IU/ml malic dehydrogenase, 0.2mM NAD, 0.067mg/ml diaphorase and 0.067mM resazurin in the assay buffer (50 mM Tris pH 8.0, 5 mM MgCl2, 0.01% Brij 3) was dispensed into each well in a black solid bottom 1536-well assay plate (Greiner Bio-One) using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). A 1536-well pintool dispenser outfitted with 20 nl pins (Wako Automation, San Diego, CA) was used to transfer 20 nL of DMSO-solubilized compound (Cherrypick plates) to each 1536-well assay plate. Each compound was screened at five concentrations: 15 nM, 151 nM, 1.5 uM, 15.4 uM, 76.9 uM. Following compound transfer, plates were incubated in room temperature for 10 minutes. 1 uL of substrate solution containing fumaric acid (160 uM) was dispensed via BioRAPTR FRD to initiate the reaction. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (exitation/emission, 525/598 nm) at 0 and 15 minutes. The exposure time is 1 second. Fluorescence from each well was normalized using enzyme-free and DMSO-treated control wells on each plate, and changes in fluorescence (delta RFU) were calculated using the difference in fluorescent signal for each well at 15 minutes versus 0 minutes.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000077118 uMActivity at 0.0000393017 uMActivity at 0.0000781896 uMActivity at 0.0001700349 uMActivity at 0.0003854776 uMActivity at 0.0008323078 uMActivity at 0.00150 uMActivity at 0.00316 uMActivity at 0.00511 uMActivity at 0.00966 uMActivity at 0.023 uMActivity at 0.050 uMActivity at 0.101 uMActivity at 0.217 uMActivity at 0.414 uMActivity at 0.673 uMActivity at 1.904 uMActivity at 2.793 uMActivity at 6.307 uMActivity at 13.45 uMActivity at 20.56 uMActivity at 53.33 uMActivity at 79.85 uMActivity at 162.3 uMActivity at 288.0 uMCompound QC
Inhibitor39.810753.320210Single point of activity-4.42.58840.9867-48.82024.5-30 0 0 0 0 0 0-40.68358.16034.08673.42765.11961.6393-0.0748-40.6835QC'd by Tocris
Inactive00040.015-0.2175-0.5756-1.11951.4974-1.0976-0.62120.015QC'd by Tocris
Inactive00040.51856.07790.55083.89162.59841.17222.06630.5185QC'd by Tocris
Inactive0004-2.0257-0.374-1.4506-1.3016-1.0656-0.92350.4464-2.0257QC'd by Tocris
Inactive0-4.34.50450.984-19.1975040 0 0 0 0 0 0-16.8312-0.2154-1.25580.97381.1829-0.1066-0.0366-16.8312QC'd by Tocris
Inactive00042.12962.96550.6465-1.98581.5085-0.08872.97092.1296QC'd by Tocris
Inactive0-4.41.85790.925-12.343440 0 0 0 0 0 0-8.61915.77951.93763.81995.45582.78381.8259-8.6191QC'd by Tocris
Inactive0004-2.0918-0.9895-2.4108-0.8469-0.967-2.0746-1.3704-2.0918QC'd by Tocris
Inactive00040.0255-0.62830.01560.1788-0.8044-1.3186-0.71530.0255QC'd by Tocris
Inactive00040.1146-2.8935-5.1856-5.7517-1.454-4.3451-6.17830.1146QC'd by MedChem Express
Inactive00043.8877-1.3858-16.616.97627.2289-13.88265.81453.8877QC'd by APExBIO
Inactive0004-3.262-4.18111.5622-0.0496-1.6578-0.2741-0.8617-3.262QC'd by Tocris
Inactive0-5.354.0950.9664-6.7999440 0 0 0 0 0 15.4374.94434.753.1663.05912-6.49995.437QC'd by Axon Medchem
Inactive0004-6.3793-1.7899-0.6034-0.4471-1.1982-1.16121.5608-6.3793QC'd by Tocris
Inactive0-4.750.80.915918-3.010640 0 0 0 0 0 013.5846-2.6459-2.5886-1.4907-4.59224.02455.379313.5846QC'd by MedChem Express
Inactive0004-0.1718-2.7451-1.5974-2.775-1.4013-1.0798-0.4332-0.1718QC'd by Tocris
Inactive0-4.254.95490.9713-25.1804-1.752740 0 0 0 0 0 0-20.9837-0.8831-2.3367-0.2106-1.3606-4.0325-0.9729-20.9837QC'd by Axon Medchem
Inactive0-4.451.64360.46727.5-7.674340 0 0 0 0 0 04.0193-6.5695-2.9715-6.8641-16.8119-3.3436-5.01744.0193QC'd by Axon Medchem
Inactive0004-8.0397-4.2819-2.9052-2.785-0.42681.6569-0.2368-8.0397QC'd by Tocris
Inactive00043.3582.45981.05123.37720.91660.32320.16613.358QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1364-MLP_WT
Protocol: The day before screening, RN4220 was grown overnight (16-18 h) in sterile-filtered tryptic soy broth (TSB) at 30 degrees C with shaking.

On the day of screening, columns 1-24 of assay plates (Corning 3710, clear) were prefilled with 30 uL of TSB using the Combi. Next, 100 nL of each compound was pin-transferred to each plate. For every compound library plate, there were two daughter plates (A & B). Overnight cultures were diluted 625x into TSB. 50 uL of the diluted cultures were added to columns 1-24 of the corresponding assay plates. Wells in column 2 contained only medium (with culture) and served as the negative controls. Positive control (0.8 uL of erythromycin, 10 ug/mL) was added to column 1 using the Hewlett Packard D300. Final assay well volume was 80 uL. Plates were spun down and stacked 5 high, covered with lids (Corning 3009), and incubated at 30 degrees C overnight (~16 h).

The following day, assay plates were removed from the incubator and cell density quantitated using a PerkinElmer EnVision (600 nm filter).
Comment: Z-scores were calculated for every well based on plate average and standard deviation of experimental well absorbance (OD600). Wells were considered active for reduced WT survival if Z-score for both replicates <= -3 and absorbance for both replicates <= 0.18. Percent inhibition was calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. The replicate values were then averaged to determine activity scores. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_WT_AAbsorbance_WT_BZ-score WT_AZ-score WT_BPercent Inhibition_WT_APercent Inhibition_WT_B
0.7370.747-1.624235685-1.0789525314.234071413.85068762
0.7480.834-1.4382629330.33116364814.991762772.84634982
0.8350.8340.0326124740.3311636482.922049772.84634982
0.7920.828-0.6943719230.2339142568.8875401023.68971273
0.9390.8961.7909003161.336074027-11.50611289-5.868400246
0.8210.844-0.204080120.4932459674.8643024361.440744971
0.8110.872-0.3731462590.9470764616.25162577-2.494948608
0.8230.872-0.1702668930.9470764614.58683777-2.494948608
0.7990.862-0.5760256250.7849941427.916413769-1.089343758
0.8480.8940.2523984541.3036575631.118529437-5.587279276
0.8410.8920.1340521571.2712410992.08965577-5.306158306
0.8660.8620.5567175040.784994142-1.378652562-1.089343758
0.8760.8650.7257836430.833618837-2.765975895-1.511025213
0.8370.8680.0664257020.8822435332.644585104-1.932706668
0.8380.8630.0833323160.8012023732.50585277-1.229904243
0.8120.844-0.3562396450.4932459676.1128934361.440744971
0.8150.877-0.3055198041.028117625.696696436-3.197751032
0.8650.8950.539810891.319865795-1.239920229-5.727839761
0.8310.88-0.0350139821.0767423163.476979103-3.619432487
0.8440.8450.1847719990.5094541991.673458771.300184486
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1364-MLP_ugtP
Protocol: The day before screening, RN4220 ugtP was grown overnight (16-18 h) in sterile-filtered tryptic soy broth (TSB) at 30 degrees C with shaking.

On the day of screening, columns 1-24 of assay plates (Corning 3710, clear) were prefilled with 30 uL of TSB using the Combi. Next, 100 nL of each compound was pin-transferred to each plate. For every compound library plate, there were two daughter plates (A & B). Overnight cultures were diluted 625x into TSB. 50 uL of the diluted cultures were added to columns 1-24 of the corresponding assay plates. Wells in column 2 contained only medium (with culture) and served as the negative controls. Positive control (0.8 uL of erythromycin, 10 ug/mL) was added to column 1 using the D300. Final assay well volume was 80 uL. Plates were spun down and stacked 5 high, covered with lids (Corning 3009), and incubated at 30 degrees C overnight (~16 h).

The following day, assay plates were removed from the incubator and cell density quantitated using a PerkinElmer EnVision (600 nm filter). Library plates were screened in duplicate, with both assay plates in a given set prepared on the same day.
Comment: Z-scores were calculated for every well based on plate average and standard deviation of experimental well absorbance (OD600). Wells were considered active for reduced ugtP survival if Z-score for both replicates < -3 and absorbance for both replicates <= 0.15. Percent inhibition was calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. The replicate values were then averaged to determine activity scores. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_ugtP_AAbsorbance_ugtP_BZ-score ugtP_AZ-score ugtP_BPercent Inhibition_ugtP_APercent Inhibition_ugtP_B
0.5140.537-1.229512579-0.52346704814.474576278.463841548
0.5470.588-0.7679522420.1914626568.508474576-0.932749885
0.6270.6070.3509819090.457809016-5.95480226-4.433440811
0.6140.6060.1691551090.443790786-3.604519774-4.24919392
0.6040.5740.02928834-0.004792557-1.7966101691.646706587
0.5640.55-0.530178735-0.3412300655.4350282496.068631967
0.6150.5740.183141786-0.004792557-3.7853107341.646706587
0.6170.6130.211115140.541918393-4.146892655-5.538922156
0.6010.604-0.012671690.415754327-1.254237288-3.880700138
0.7040.71.4279560291.761504358-19.87570621-21.56840166
0.6240.6150.3090218780.569954852-5.412429379-5.907415937
0.6450.6110.6027420930.513881934-9.209039548-5.170428374
0.5440.599-0.8099122730.3456631810.06359478-2.989036353
0.5620.617-0.5581520890.5979913116.850384916-6.312752452
0.5490.594-0.7399788880.2755720339.171036483-2.065781881
0.560.63-0.5861254420.7802282947.207408234-8.71321408
0.5690.545-0.46024535-0.4113212125.6008033026.982111945
0.5350.554-0.935792365-0.28515714711.670199715.320253895
0.5170.525-1.187552548-0.69168580214.8834095710.67512983
0.5130.534-1.243499256-0.56552173615.597456219.013271783